platinum has been researched along with carboplatin in 320 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (8.13) | 18.7374 |
| 1990's | 84 (26.25) | 18.2507 |
| 2000's | 38 (11.88) | 29.6817 |
| 2010's | 90 (28.13) | 24.3611 |
| 2020's | 82 (25.63) | 2.80 |
| Authors | Studies |
|---|---|
| Guthrie, D; Parmar, M; Stewart, L; Williams, CJ | 1 |
| Fox, BW; Jackson, H; McAuliffe, CA; Perera, A; Sharma, HL | 1 |
| Kumazawa, J; Mihara, Y; Ueda, T; Uozumi, J; Yasumasu, T | 1 |
| Klys, HS; Matheson, LM; McKay, K; Smyth, JF; Tothill, P | 1 |
| Allegra, C; Jacob, J; Ozols, RF; Reed, E; Young, RC | 1 |
| Harrap, KR; Nicolson, MC; O'Neill, CF; Orr, RM | 1 |
| Hoskins, W; Markman, M | 1 |
| Zhang, M | 1 |
| den Engelse, L; Los, G; McVie, JG; Pinedo, HM; Smals, OA; van der Vlist, M; van Vugt, MJ | 1 |
| van der Vijgh, WJ | 1 |
| Dykes, PJ; Featherstone, J; Marks, R | 1 |
| Brann, TW; Frei, E; Herman, TS; Holden, SA; Khandekar, V; Korbut, TT; Rosbe, KW; Sotomayor, EA; Teicher, BA | 1 |
| Eguchi, K; Ohe, Y; Ohmori, T; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| de Graeff, A; Los, G; McVie, JG; Meesters, EW; Noteborn, HP; Ruevekamp, M; ten Bokkel Huinink, D; Verdegaal, E | 1 |
| Arimoto, T; Fujii, T; Fujita, Y; Gotoh, T; Hiramori, N; Iwasaki, Y; Kida, T; Nakagawa, M; Nakamura, T; Sakai, M | 1 |
| Crowther, D; Lind, MJ; McAuliffe, CA; Murphy, DJ; Sharma, H; Smith, A; Tinker, N | 1 |
| Baumann, K; Duwe, J; Hannemann, J | 1 |
| Ueda, T; Uozumi, J; Yasumasu, T | 1 |
| de Vries, EG; Meijer, S; Mulder, NH; Postmus, PE; Sleijfer, DT; Smit, EF; Terheggen, PM; Uges, DR; Willemse, PH | 1 |
| Christian, MC; den Engelse, L; Gill, I; Grunberg, S; Kortes, V; Michael, C; Muggia, FM; Parker, RJ; Reed, E; Terheggen, PM | 1 |
| Gill, I; Grunberg, S; Muggia, FM; Parker, RJ; Reed, E; Tarone, R; Vionnet, JA | 1 |
| de Leij, L; de Vries, EG; Hospers, GA; Meijer, C; Mulder, NH; Uges, DR | 1 |
| Baumann, K; Hannemann, J | 1 |
| Ostchega, Y; Ozols, RF; Poirier, MC; Reed, E; Steinberg, SM; Young, RC; Yuspa, SH | 1 |
| Ewen, C; Hendry, JH | 1 |
| De Spiegeleer, B; Jackson, H; McAuliffe, C; Reman, JP; Sharma, H; Tinker, N | 1 |
| Binks, SP; Dobrota, M | 1 |
| Azouri, H; Bidart, JM; Bohuon, C | 1 |
| Abrams, MJ; Chan, V; Collins, LS; Herman, TS; Teicher, BA | 1 |
| Antman, K; Begg, C; Eder, JP; Elias, A; Flaherty, M; Frei, E; Henner, WD; Schnipper, L; Shea, TC | 1 |
| Fujita, H; Okamoto, M; Takao, A | 1 |
| Majima, H | 1 |
| Amer, M; el-Yazigi, A; Martin, CR | 1 |
| Ewen, C; Fox, BW; Hendry, JH; McAuliffe, CA; Perera, A; Sharma, H | 1 |
| Canetta, RM; Colombo, N; Deeb, G; Farmen, RH; Gaver, RC; George, AM; Green, MD; Morris, AD; Muggia, FM; Speyer, JL | 1 |
| Dubbelman, R; Elferink, F; Klein, I; McVie, JG; ten Bokkel Huinink, WW; van der Vijgh, WJ | 1 |
| Douple, EB; Spencer, F; Totten, MD | 1 |
| Ishikawa, K; Kimura, K; Mase, H; Oguri, S; Sakakibara, T; Shimizu, T; Smyth, RD | 1 |
| Fujiwara, K; Hayase, R; Kobashi, Y; Kohno, I; Miyagi, Y; Sekiba, K; Yoshinouchi, M | 1 |
| Dible, SE; Harrap, KR; Siddik, ZH | 1 |
| Adenis, L; Caty, A; Fournier, C; Hecquet, B; Lefebvre, JL | 1 |
| Boxall, FE; Calvert, AH; Gore, ME; Gumbrell, LA; Newell, DR; Siddik, ZH; Smith, IE | 1 |
| Elferink, F; Gall, HE; Klein, I; Pinedo, HM; van der Vijgh, WJ; Vermorken, JB | 1 |
| Friedlos, F; Knox, RJ; Lydall, DA; Roberts, JJ | 1 |
| Adenis, L; Hecquet, B; Lefebvre, JL; Leroy, A; Peyrat, JP | 1 |
| Cucchi, CA; Frei, E; Henner, WD; Holden, SA; Kelley, MJ; Rosowsky, A; Shea, TC; Teicher, BA | 1 |
| Baer, J; Harrison, R; McAuliffe, CA; Sharma, HL; Smith, AG; Zaki, A | 1 |
| Coughlin, CT; Douple, EB; O'Hara, JA; Richmond, RC | 1 |
| Dubbelman, R; Franklin, H; Klein, I; McVie, JG; ten Bokkel Huinink, W; van der Vijgh, W | 1 |
| Kidani, Y | 1 |
| Calvert, AH; Chadwick, R; Harland, SJ; Harrap, KR; Newell, DR; Siddik, ZH | 1 |
| Aisner, J; Egorin, MJ; Olman, EA; Van Echo, DA; Whitacre, MY | 1 |
| Balázová, E; Hrubisko, M; Ujházy, V | 1 |
| Akaboshi, M; Kawai, K; Miyahara, T; Takada, S; Ujeno, Y | 1 |
| Bosl, GJ; Motzer, RJ; Parker, RJ; Perera, F; Poirier, MC; Reed, E; Shamkhani, H; Tang, D; Tsai, WY | 1 |
| Ishihara, H; Itamochi, H; Kanamori, Y; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Li, M; Liu, J | 1 |
| Douple, EB; O'Hara, JA; Wang, HJ; Yang, LX | 1 |
| Chen, JT; Hasumi, K | 1 |
| Blommaert, FA; Saris, CP | 1 |
| Leibbrandt, ME; Wolfgang, GH | 1 |
| de Vries, EG; Esselink, MT; Guchelaar, HJ; Meijer, C; Mulder, NH; Uges, DR; Vellenga, E | 1 |
| Amorusi, P; Bansal, SK; Lessard, D; Selinger, K; Tonelli, AP; Yacobi, A | 1 |
| Kikkawa, F; Kojima, M; Maeda, O; Oguchi, H; Suganuma, N; Tamakoshi, K; Tomoda, Y | 1 |
| Adams, M; Fish, RG; Griffiths, H; James, K; Mason, M; Shelley, MD | 1 |
| de Boer-Dennert, M; Ma, J; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; van Ingen, HE; Verweij, J | 1 |
| Boughattas, NA; Bouzouita, K; Bruguerolle, B; Fournier, C; Hecquet, B; Lévi, F; Omrane, B; Trabelsi, H | 1 |
| Chang, MJ; Egorin, MJ; Erkmen, K; Furmanski, P; Johnson, CS; Modzelewski, RA; Reyno, LM; Vlock, DR; Yu, WD | 1 |
| Frenkel, EP; Henner, WD; Mickey, BE; Neuwelt, EA; Wiliams, PC | 1 |
| Cooper, KG; Kitchener, HC; Parkin, DE | 1 |
| Asanami, S; Susami, E; Uchiyama, K | 1 |
| Murakami, T; Nagai, N; Ohama, K | 1 |
| Akiyama, K; Hongo, A; Kudo, T; Seki, S | 1 |
| al-Sadhan, FA; Ali, PA; Dutton, J; el-Sharkawi, AM; Evans, CJ; Hancock, DA; Lewis, DG | 1 |
| Cho, T; Ikarashi, H; Kaneko, T; Kodama, S; Kurata, H; Suzuki, E; Suzuki, K; Tanaka, K; Yoshiya, N; Yoshizawa, H | 1 |
| den Engelse, L; Los, G; Pinedo, HM; van Vugt, MJ | 1 |
| Benatti, U; De Flora, A; Gasparini, A; Giovine, M; Tonetti, M | 1 |
| Blommaert, FA; den Engelse, L; Hart, AA; Kortes, V; Michael, C; Muggia, FM; Schornagel, JH; Terheggen, PM | 1 |
| Baskett, G; Chu, G; Mantin, R; Shen, YM; Sussman, H | 1 |
| Los, G; Muggia, FM | 1 |
| Baba, H; Kusumoto, H; Kusumoto, T; Maehara, Y; Ohno, S; Sugimachi, K; Takahashi, I | 1 |
| Klein, J; Koren, G; Moselhy, G; Weitzman, S | 1 |
| Adelstein, D; Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Gibson, V; McLain, D; Murthy, S; Sergi, J; Weick, J | 1 |
| Coquery, L; Courjault, F; Leroy, D; Toutain, H | 1 |
| Page, RL; Riviere, JE; Vaden, SL; Williams, PL | 1 |
| Baur, M; Dittrich, C; Fazeny, B; Grunt, T; Hudec, M; Marth, C; Salzer, H; Sevelda, P; Vavra, N | 1 |
| Bijnen, JH; Maes, RA; Rodenhuis, S; ten Bokkel Huinink, WW; van Tellingen, O; van Warmerdam, LJ | 1 |
| Calvert, AH; Ghazal-Aswad, S; Newell, DR | 1 |
| Rau, T; van Eldik, R | 1 |
| Ma, J; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Chan, KK; Formenti, SC; Jeffers, S; Jozsef, G; Morrow, PC; Muggia, FM; Sapozink, M; Shrivastava, PN | 1 |
| Akamo, Y; Manabe, T; Mizuno, I; Mohri, N; Shibata, T; Takeyama, H; Terada, J; Ueda, T; Yamamoto, T; Yotsuyanagi, T | 1 |
| Hayashi, N; Ikeba, K; Kinoshita, K; Ohokubo, T; Sodemoto, T; Takagi, A; Takeda, S; Yamamoto, T | 1 |
| Kimbara, K; Kunitoh, H; Nagatomo, A; Okamoto, H; Watanabe, K | 1 |
| Bach, PH; Sharma, P | 1 |
| Boven, E; Fichtinger-Schepman, AM; Korst, AE; van der Sterre, ML; van der Vijgh, WJ | 1 |
| Bagarry-Liegey, D; Catalin, J; Duffaud, F; Durand, A; Favre, R; Guillet, P; Lacarelle, B; Monjanel, S; Nicoara, A | 1 |
| Akaboshi, M; Kawai, K; Masunaga, S; Miyahara, T; Ono, K; Sumino, T; Tanaka, Y | 1 |
| Hoshi, S; Mao, H; Nose, M; Orikasa, S; Suzuki, K; Takahashi, T | 1 |
| Fluellen, L; Fusco, N; Rodriguez, M; Rose, PG | 1 |
| Bachert, P; Becker, M; Port, RE; Zabel, HJ; Zeller, WJ | 1 |
| Bench, G; Mauthe, RJ; Sideras-Haddad, E; Turteltaub, KW | 1 |
| Apostoli, P; Bonetti, A; Cetto, GL; Colombatti, M; Franceschi, T; Leone, R; Pavanel, F; Sperotto, L; Zaninelli, M | 1 |
| Bernhardt, G; Gust, R; Hummel, E; Koch, M; Krauser, R; Schmid, B; Schnurr, B; Schönenberger, H | 1 |
| Helmers, E; Hubner, P; Kümmerer, K; Mascart, G; Milandri, M; Reinthaler, F; Zwakenberg, M | 1 |
| Johannes, WU; Miller, GJ; Moffatt, KA | 1 |
| Hamácek, J; Havel, J | 1 |
| Heydorn, K; Krarup, C; Krarup-Hansen, A; Rietz, B; Rørth, M; Schmalbruch, H | 1 |
| Appelius, H; Jaehde, U; Kloft, C; Schunack, W; Siegert, W | 1 |
| al-Hussany, A; Ali, PA; el-Sharkawi, AM; Hancock, DA; Kadhim, R | 1 |
| Agostino, M; Bartus, RT; Emerich, DF; Marsh, J; Perkins, A; Snodgrass, P | 1 |
| Fujiwara, K | 1 |
| Comerci, JT; Edwards, RP; Kanbour-Shakir, A; Kelley, JL; Kunschner, AJ; Price, FV; Sit, AS | 1 |
| Fujiwara, K; Fujiwara, M; Ishikawa, H; Kohno, I; Suzuki, S; Tanaka, Y; Yamauchi, H | 1 |
| Aiba, K; Akaza, H; Hoctin-Boes, G; Isonishi, S; Kawai, K; Konishi, T; Mikami, O; Miki, T; Noguchi, S; Ohashi, Y; Saeki, T; Saijo, N; Smith, M; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Jun, MJ; Kim, KM; Kim, YS; Sohn, YS; Song, R | 1 |
| Aghajanian, C; Dizon, DS; Hensley, ML; Hummer, A; Poynor, EA; Sabbatini, P; Spriggs, DR; Venkatraman, E | 1 |
| Adjei, AA; Alberts, SR; Ames, MM; Atherton, P; Boemer, SA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Pitot, HC; Reid, JM; Ruben, S; Sloan, JA | 1 |
| Greco, FA | 1 |
| Goodisman, J; Hagrman, D; Souid, AK | 1 |
| Carson, BS; Gillis, EM; Guarnieri, M; Jallo, GI; Johnson, RM; Kiely, A; Liu, YJ; Storm, P; Strege, RJ | 1 |
| Holzer, AK; Howell, SB; Katano, K; Safaei, R; Samimi, G | 1 |
| Goodman, M; Holzer, AK; Howell, SB; Katano, K; Rochdi, M; Safaei, R; Samimi, G; Tomioka, M | 1 |
| Guo, Y; Petris, MJ; Smith, K | 1 |
| Bailey, DB; Dykes, NL; Erb, HN; Hoopes, PJ; Page, RL; Rassnick, KM | 1 |
| Chen, CL; Liang, LZ; Sun, MH; Tan, DC | 1 |
| Sugiyama, T | 1 |
| Chang, HM; Choi, SJ; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, YH; Ryu, BY | 1 |
| Au-Yeung, SC; Ho, YP; Li, KK; Pang, SK; Yu, CW | 1 |
| Lautermann, J; Liedert, B; Seiler, F; Thomale, J; Thomas, JP | 1 |
| Hotta, K; Kiura, K | 1 |
| de Kroon, AI; de Kruijff, B; Hamelers, IH; Staffhorst, RW; van Loenen, E | 1 |
| Beijnen, JH; Brouwers, EE; Hillebrand, MJ; Joerger, M; Rosing, H; Schellens, JH; Tibben, MM | 1 |
| Collet, E; Coudert, B; Dalac, S; Jolimoy, G; Leguy-Seguin, V; Pernot, C; Vabres, P | 1 |
| Alimonti, A; Bocca, B; Cappelli, C; Caroli, S; Clerico, A; De Ioris, MA; Petrucci, F; Ragni, G; Sordi, A | 1 |
| Jett, JR; Keith, RL; Kesler, KA; Schild, SE | 1 |
| Esteban-Fernández, D; Gómez-Gómez, MM; Palacios, MA; Ramírez-Camacho, R; Verdaguer, JM | 1 |
| Carson, BS; Guarnieri, M; Jallo, GI | 1 |
| Chen, X; Hou, S; Liu, W; Lou, L; Xie, M; Ye, Q; Yu, Y | 1 |
| Blair, BG; Howell, SB; Larson, CA; Safaei, R | 1 |
| Ito, K; Kaneyasu, Y; Komatsu, M; Nagai, N; Oshita, T; Shiroyama, Y; Watasaki, S | 1 |
| Daneriallis, GM; Egorin, MJ; Goldman, S; Kondo, A; Mania-Farnell, B; Nakazaki, H; Rajaram, V; Soares, MB; Sredni, ST; Tange, Y; Tomita, T | 1 |
| Arakawa, K; Ehara, S; Harada, S; Ishii, K; Ito, J; Kamiya, T; Matsuyama, S; Oikawa, S; Sato, T; Sera, K; Yamazaki, H; Yokota, W | 1 |
| Aggarwal, S; Gambrell, RP; Hammer, RP; Ndinguri, MW; Solipuram, R | 1 |
| Farshchi-Heydari, S; Howell, SB; Jandial, DD; Messer, K; Pu, M | 1 |
| Bellanger, A; Caudron, E; Chappuy, M; Pradeau, D | 1 |
| Fusch, EC; Holland, L; Krizanovic, O; Lax, PM; Lippert, B; Lutterbeck, M; Roitzsch, M; Sanz Miguel, PJ; Schürmann, M; Yin, L | 1 |
| Arambula, JF; Fountain, ME; Magda, D; Sessler, JL; Siddik, ZH; Wei, WH | 1 |
| Gumus, F; Ozkul, A; Serin, MS; Tezcan, S; Utku, S | 1 |
| Eileen Dolan, M; Gamazon, E; Kistner-Griffin, EO; O'Donnell, PH; Stark, AL; Stephanie Huang, R; Zhang, W | 1 |
| Ang, WH; Lippard, SJ; Myint, M | 1 |
| Guan, Y; Lin, D; Liu, Y; Liu, Z; Ott, J; Shen, Y; Wu, C; Xu, B; Yu, D; Yuan, P | 1 |
| Aavall-Lundqvist, E; Brown, C; du Bois, A; Ferrero, A; Gebski, V; Heywood, M; Jackisch, C; Joly, F; Kristensen, G; Le Fur, N; Lortholary, A; Pignata, S; Pujade-Lauraine, E; Sehouli, J; Vasey, PA; Vergote, I; Volgger, B; Wagner, U | 1 |
| Alves, NJ; Berkowitz, J; Bilgicer, B; Chaudhuri, P; Chin, KT; Dinulescu, DM; Handlogten, MW; Mashelkar, RA; Muto, KW; Paraskar, AS; Sengupta, S; Soni, S | 1 |
| Dvorák, Z; Starha, P; Trávnícek, Z; Vrzal, R | 1 |
| Beijnen, JH; Brouwers, EE; de Vos, JP; Janssens, T; Schellens, JH | 2 |
| Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
| Chen, P; Cohen, EE; Cox, NJ; Das, S; Delaney, S; Dolan, ME; Gamazon, ER; Huang, RS; Im, HK; O'Donnell, PH; Shukla, S; Vokes, EE; Ziliak, D | 1 |
| de Carvalho, LA; Marques, MP; Martin, C; Parker, SF; Tomkinson, J | 1 |
| Berchuck, A; Havrilesky, LJ; Higgins, RV; Kohler, MF; Myers, ER; Nycum, LR; Pokrzywinski, R; Revicki, D; Secord, AA | 1 |
| Aso, M; Ekimoto, H; Nakatake, H; Ogawa, A; Suemune, H; Yamaguchi, A | 1 |
| Georgoulias, V; Pallis, AG | 1 |
| Bandyopadhyay, D; Dabrowiak, JC; Luk, YY; Prashar, D; Shi, Y | 1 |
| Alvarez Secord, A; Berchuck, A; Havrilesky, LJ; Higgins, RV; Holloway, RW; Kohler, MF; Lewandowski, GS; Nycum, LR; Puls, LE; Valea, FA | 1 |
| Chen, X; Dong, C; Han, D; Li, C; Lin, H; Ren, S; Wang, X; Xu, C; Yang, S; Zhang, L; Zhang, Y; Zhao, D | 1 |
| Avila, J; Cortés, P; Gill, M; Pizarro, I; Rivera, L; Román, DA; Torres, C | 1 |
| Kotani, A; Kusu, F; Otsuki, Y | 1 |
| Bonaventura, T; Brown, C; Fossati, R; Gebski, V; Heywood, M; Kaern, J; Largillier, R; Lauraine, EP; Marth, C; Piccirillo, MC; Vergote, I; Wagner, U | 1 |
| de Carvalho, AL; Lopes, RP; Marques, MP; Matos, CS | 1 |
| Chow, CW; Fujimoto, J; He, G; Kalhor, N; Kim, ES; Lee, JJ; Siddik, ZH; Stewart, DJ; Swisher, SG; Wistuba, II | 1 |
| Brauckmann, C; Karst, U; Kieshauer, M; Lanvers-Kaminsky, C; Sperling, M; Wehe, CA | 1 |
| Guan, ZZ; Guo, Y; Huang, H; Jiang, WQ; Li, S; Liao, H; Yang, XQ; Zhan, J; Zou, BY | 1 |
| Duan, Z; He, C; Li, P; Xu, Q; Yuan, Y | 1 |
| Galanski, MS; Jakupec, MA; Jensen, F; Keppler, BK; Roller, A; Varbanov, HP | 1 |
| Beijnen, JH; Brouwers, EE; de Vos, JP; de Vries, N; Janssens, T; Schellens, JH | 2 |
| Blackstock, AW; Bogart, JA; Crawford, J; Hodgson, L; Pang, H; Salama, JK; Schild, SE; Urbanic, JJ; Vokes, EE | 1 |
| am Zehnhoff-Dinnesen, A; Langer, T; Meitert, J; Radtke, S; Zolk, O | 1 |
| Nørøxe, DS; Sørensen, JB; Wallerek, S | 1 |
| Chien, CT; Chiu, WC; Lin, SY; Liu, CY; Wu, TH; Yan, JY | 1 |
| Eaddy, M; Green, MR; Gruschkus, SK; Peterson, P; Shah, M; Winfree, KB | 1 |
| Aldrich-Wright, JR; Garbutcheon-Singh, KB; Harper, BW; Myers, S | 1 |
| Ambriović-Ristov, A; Arany, I; Brozovic, A; Fiket, Z; Fritz, G; Köberle, B; Majhen, D; Osmak, M; Polančac, DS; Vuković, L | 1 |
| Cemazar, M; Kovač, V; Martinčič, A; Milačič, R; Ščančar, J; Sersa, G | 1 |
| Gómez-Gómez, MM; Mena, ML; Moreno-Gordaliza, E | 1 |
| González, A | 1 |
| Carty, MP; Cruet-Hennequart, S; Pasero, P; Sokol, AM | 1 |
| Kumar, SJ; Madhavi, K; Manjusha, R; Meeravali, NN | 1 |
| Au-Yeung, CF; Ho, YP; Pang, SK; So, WK | 1 |
| Appleton, K; Brown, R; Gabra, H; Glasspool, RM; Gore, ME; Halford, SE; Hall, GD; Kaye, S; Mackean, M; McNeish, IA; Paul, J; Pledge, S; Rustin, GJ; Ullah, R; Walker, J; Wilson, RH | 1 |
| Jangir, DK; Mehrotra, R | 1 |
| Açık, L; Arsoy, T; Celebi Keskin, A; Gümüş, F; Ozçelik, AB; Utku, S; Yılmaz, S | 1 |
| Li, KM; Tong, LX; Xiao, P; Xie, D; Yin, RT | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Esteban-Fernández, D; Gómez-Gómez, MM; Linscheid, MW; Mena, ML; Moraleja, I; Moreno-Gordaliza, E | 1 |
| Bamias, A; Dimopoulos, MA; Episkopou, H; Gavalas, N; Kalampokas, T; Kyrtopoulos, SA; Likka, M; Photiou, S; Sfikakis, PP; Souliotis, VL; Stefanou, DT | 1 |
| Bremnes, RM; Brydøy, M; Fosså, SD; Gundersen, PO; Haugnes, HS; Hjelle, LV; Oldenburg, J; Tandstad, T; Wilsgaard, T | 1 |
| Aftimos, PG; Awada, A; Bartholomeus, S; Berghmans, T; Cescutti, J; Costermans, J; Dumez, H; Forceville, K; Liu, D; Meeus, MA; Munzert, G; Pilz, K; Schöffski, P | 1 |
| Chen, YM; Lee, YC; Lin, YH; Perng, RP; Tseng, YC; Tseng, YH; Whang-Peng, J | 1 |
| Wang, Z; Xu, Z; Yiu, SM; Zhu, G | 1 |
| Galanski, MS; Göschl, S; Jakupec, MA; Keppler, BK; Theiner, S; Varbanov, HP | 1 |
| Hu, Z; Sun, C; Wang, W; Yao, H | 1 |
| Alard, A; Blank, SV; Curtin, JP; David-West, G; Musa, F; Schneider, RJ | 1 |
| Bamias, A; Chatziioannou, A; Dimopoulos, MA; Gavalas, NG; Haidopoulos, D; Kostouros, E; Koutsoukos, K; Liontos, M; Lykka, M; Papadodima, O; Pilalis, E; Rodolakis, A; Terpos, E; Thomakos, N; Trachana, SP; Tzannis, K; Vlachos, G | 1 |
| Chan, C; Duan, X; Han, W; Lin, W; Poon, C | 1 |
| Altwerger, G; Azodi, M; Carusillo, N; English, DP; Gressel, GM; Nelson, WK; Ratner, ES; Santin, A; Schwartz, PE; Silasi, DA | 1 |
| Dirikolu, L; Garrett, LD; Mitchell, MA; Phillips, H; Tulipan, RJ | 2 |
| Ab, O; Bartle, LM; Coccia, J; Lanieri, L; Lee, J; Pinkas, J; Ponte, JF; Ruiz-Soto, R; Themeles, M; Zhou, Y | 1 |
| Airhart, S; Chamie, K; Cimino, GD; de Vere White, R; Drakaki, A; Haack, K; Henderson, PT; Lin, TY; Malfatti, M; Ognibene, T; Pan, CX; Tepper, CG; Turteltaub, KW; Wang, SS; Yang, H; Zhang, H; Zimmermann, M | 1 |
| Hummon, AB; Liu, X | 1 |
| Anisimov, VN; Drobyshev, EJ; Fedoros, EI; Ivanenko, NB; Panchenko, AV; Pigarev, SE; Solovyev, ND; Tyndyk, ML; Vilpan, YA | 1 |
| Hyman, DM; Iasonos, A; Schram, AM | 1 |
| Boon, N; De Smet, R; Fitts, JP; Hennebel, T; Maes, S; Props, R; Vanhaecke, F | 1 |
| McQuade, R; Nurgali, K; Rybalka, E; Stojanovska, V | 1 |
| Afghahi, A; Carlson, RW; Chang, PJ; Ford, JM; Hartman, AR; Jensen, KC; Kurian, AW; Schackmann, E; Telli, ML; Timms, KM; Vinayak, S | 1 |
| Han, ZG; Shan, L; Tao, J; Yu, TT | 1 |
| Amato, LB; Bucci, C; Dusi, S; Gasparre, G; Girolimetti, G; Guerra, F; Iommarini, L; Kurelac, I; Leone, G; Maffia, M; Perrone, AM; Porcelli, AM; Tiranti, V; Vergara, D; Vidone, M | 1 |
| Dewkar, GK; Lamichhane, N; Mahon, RN; Sundaresan, G; Zweit, J | 1 |
| Gao, H; He, K; Li, L; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, L; Wang, W; Xu, B; Yang, L | 1 |
| Adam, V; Brtnicky, M; Eckschlager, T; Hubalek, J; Kynicky, J; Smerkova, K; Stiborova, M; Vaculovic, T; Vaculovicova, M | 1 |
| Chen, F; Gou, S; Jin, X; Zhao, J | 1 |
| Hayashi, R; Hayashi, Y; Koide, T; Masuda, R; Nose, H; Taguchi, A; Yasui, H | 1 |
| Cheung, S; Griffith, DM; Kitteringham, E; O'Shea, DF; Twamley, B; Wu, D | 1 |
| Curigliano, G | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Hashimoto, H; Kontani, K; Mimura, M; Miyatake, T; Nagamatsu, M; Nishikawa, A; Takeda, M; Yokoi, T | 1 |
| Alamgeer, M; Barrow, R; Boolell, V; Burgess, A; Cain, JE; Chin, V; Croucher, DR; de Kretser, DM; Ganju, V; Gonzalez-Rajal, A; Han, JZR; Harrison, CA; Hastings, JF; Hedger, MP; Jayasekara, WSN; Kita, B; Kostyrko, K; Kumar, B; Lee, HC; Lorensuhewa, N; Marini, KD; Marquez, C; Martelotto, LG; McCloy, RA; Oakes, SR; Robinson, BW; Rossello, FJ; Sweet-Cordero, EA; Szczepny, A; Vaghjiani, V; Watkins, DN; Waugh, T; Wu, J | 1 |
| DeYonker, NJ; Duplanty, M; Khan, S; Lozano, HC; Mirsaleh-Kohan, N; Morris, TJ; Nguyen, T; Rostovtsev, YV; Torres, M | 1 |
| Fan, TM; Maxwell, EA; Phillips, H; Schaeffer, DJ | 1 |
| de Vere White, R; Henderson, PT; Malfatti, MA; Pan, CX; Scharadin, TM; Turteltaub, KW; Wang, S; Zimmermann, M | 1 |
| Berkowitz, B; Dror, I; Goykhman, N | 1 |
| Brooks, B; Carleton, B; Clemens, E; de Vries, ACH; van den Heuvel-Eibrink, MM; van Grotel, M | 1 |
| Arnaiz, MD; Aso, S; Bergamino, M; Brao, I; Cardenal, F; Montanya, E; Nadal, E; Navarro, A; Padrones, S; Palmero, R; Peiró, I; Ruffinelli, JC; Rullan, AJ; Saigí, M | 1 |
| Eskandari, A; Ghosh, S; Kundu, A; Suntharalingam, K | 1 |
| Ciofi, L; Cirri, D; Fabbrini, MG; Marzo, T; Massai, L; Messori, L; Pratesi, A | 1 |
| Adjei, AA; Aubry, MC; Bertino, E; Dakhil, SR; Dy, GK; Lee Hann, C; Mandrekar, SJ; Molina, JR; Nieva, JJ; Sachs, BA; Schenk, EL; Schild, SE; Tan, AD; Wadsworth, TW | 1 |
| Al-Chamali, H; Bird, T; Cox, C; Dorey, N; Gomberg, S; Goody, R; Hingorani, M; Hurt, C; Macgregor, U; Mukherjee, S; Owens, R; Pan, S; Parikh, S; Prince, S; Radhakrishna, G | 1 |
| Ishiki, H; Kiuchi, D; Kubo, E; Satomi, E; Shimizu, M; Tanaka, T; Yokota, S | 1 |
| Clark-Price, SC; Fan, TM; Maxwell, EA; Phillips, H; Schaeffer, DJ; Selmic, LE; Vieson, MD | 1 |
| Burotto, M; Caglevic, C; Cortés Fuentes, IA; Frelinghuysen, M; Gormaz, JG; Retamal, MA | 1 |
| Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Mahmoud, H | 1 |
| Alcaraz-Sanabria, A; Burgos, M; Corrales-Sanchez, V; Galan-Moya, EM; Martinez-Canales, S; Montero, JC; Nieto-Jimenez, C; Nuncia-Cantarero, M; Ocaña, A; Pandiella, A | 1 |
| Lynce, F; Nunes, R | 1 |
| Hoare, JI; Lockley, M; Martin, SA; Metcalf, S; Nicolini, F; Saxena, J; Silva, VL | 1 |
| Fujiwara, H; Fujiwara, K; Kanuma, T; Nakamura, K; Nakamura, Y; Sakurai, M; Satoh, T; Suzuki, M; Takahashi, S; Takei, Y | 1 |
| Fujishiro, H; Hamao, S; Himeno, S; Sumi, D; Taguchi, H | 1 |
| Apaijai, N; Charoenkwan, K; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Khunamornpong, S; Kingnate, C; Kumfu, S | 1 |
| Han, XH; Liu, S; Shi, YY; Yang, R | 1 |
| Kim, HS; Lee, M; Lee, N; Lee, S; Paik, H; Park, SJ; Yim, GW | 1 |
| Chawla, PA; Sharma, R; Singh, VJ | 1 |
| Belda, B; Messenger, KM; Ramos-Vara, J; Risselada, M | 1 |
| Cadoo, KA; Chambers, SK; Chen, LM; Chmielecki, J; Cragun, JM; Geenen, JJJ; Ghamande, SA; Hamilton, EP; Jones, SF; Konecny, GE; Kumar, S; Lai, Z; Moore, KN; Mugundu, GM; Oza, AM; Plaxe, SC; Rodrigo Imedio, E; Spigel, DR; Spitz, DL; Troso-Sandoval, TA | 1 |
| Abdel-Rahman, O; Koski, SL | 1 |
| Hirayama, Y; Kato, M; Kuratsukuri, K; Otoshi, T; Takeyama, Y; Uchida, J; Yamamoto, S; Yamasaki, T; Yukimatsu, N | 1 |
| Katsuda, T; Matsukuma, K; Nasu, H; Nishio, S; Park, J; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T | 1 |
| Brigato, F; De Corso, E; Fetoni, AR; Galli, J; Lucidi, D; Ruggiero, A; Scarano, E; Sergi, B | 1 |
| Gao, X; Xu, C; Yao, Q; Zhang, C | 1 |
| Crabb, SJ; Hack, J | 1 |
| Chen, S; Deng, Z; Liu, G; Shi, J; Wang, N; Wang, Z; Yao, H; Zhou, J; Zhu, G | 1 |
| Hu, Z; Liao, J; Liu, C; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, Y; Zhao, X | 1 |
| Bignotti, E; Bugatti, M; Calza, S; Capoferri, D; Lonardi, S; Odicino, F; Pijnenborg, JMA; Ratti, M; Ravaggi, A; Reijnen, C; Romani, C; Sartori, E; Tognon, G; Zanotti, L | 1 |
| Cheong, TF; Chiang, KY; Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Abu-Hejleh, T; Allen, BG; Bellizzi, AM; Bodeker, KL; Bossler, AD; Buatti, JM; Buettner, GR; Byrne, MM; Cullen, JJ; Fath, MA; Furqan, M; Hartwig, SM; Henrich, JB; Houtman, JC; Ivanovic, M; Mani, H; Monga, V; Mott, SL; Petronek, M; Pulliam, CF; Smith, BJ; Spitz, DR; Stephens, LM; Varga, SM; Wagner, BA; Zeitler, W; Zhang, J | 1 |
| Jalili, A; Kinaciyan, T; Marquart, E; Mothes-Luksch, N; Wagner, SN | 1 |
| Boellaard, TN; de Feijter, JM; Einerhand, SMH; Hendricksen, K; Schaake, EE; van de Kamp, MW; van der Heijden, MS; van Dijk, N; van Dorp, J; van Montfoort, ML; van Rhijn, BWG | 1 |
| Berretta, M; Cocetta, V; Giacomini, I; Montopoli, M; Ragazzi, E; Rosato, B; Tinazzi, M | 1 |
| Am Zehnhoff-Dinnesen, A; Ansari, M; Kompis, M; Kuehni, CE; Mader, L; Parfitt, R; Sláma, T; Strebel, S; von der Weid, NX; Waespe, N; Weiss, A | 1 |
| Chadha, S; Dillard, LK; Fullerton, AM; Lopez-Perez, L; Martinez, RX; McMahon, CM | 1 |
| Clarke, RG; Ferguson, MJ; Hiom, KJ; Nicholson, HA; Sawers, L; Smith, G | 1 |
| Alassadi, S; Pisani, MJ; Wheate, NJ | 1 |
| Anari, F; Geynisman, DM; Ghatalia, P; Handorf, E; Miron, B; Plimack, ER; Zarrabi, K; Zibelman, MR | 1 |
| He, ZY; Li, DC; Li, HY; Li, SJ; Liang, ZZ; Yan, J | 1 |
| Balakrishnan, AJ; Janardhanan, P; Pilankatta, R; Somasundaran, AK | 1 |
| Graham, TA; Haughey, MJ; Hoare, JI; Hockings, H; Huang, W; Lockley, M; Maniati, E; McNeish, IA; Mirza, H; Nicolini, F; Saxena, J; Silva, VL; Wood, GE | 1 |
| Alessio, E; Burckel, P; Gandioso, A; Gasser, G; Vidal, A | 1 |
| Berger, J; Boisen, M; Buckanovich, R; Coffman, LG; Courtney-Brooks, M; Edwards, RP; Frisbie, LG; Griffith, K; Lesnock, J; Liu, T; Mahdi, H; McLean, K; Normolle, D; Olawaiye, A; Orellana, TJ; Sukumvanich, P; Taylor, SE; Uppal, S | 1 |
| Cao, L; Fan, Y; Fang, J; He, J; Hu, J; Liu, W; Liu, Y; Lu, S; Shi, J; Wang, Z; Xia, J; Yi, J; Zhou, J | 1 |
| Imai, H; Kaburagi, T; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Masubuchi, K; Minato, K; Minemura, H; Nagai, Y; Shiihara, J; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y | 1 |
| Barletta, JA; Bosma-Moody, A; Camp, S; Carey, E; Conway, J; Crowdis, J; Dietlein, F; Han, S; He, MX; Huang, J; Imamovic, A; Kofman, E; Liu, D; Lorch, JH; Pappa, T; Park, J; Reardon, B; Schiantarelli, J; Shannon, E; Stanizzi, D; Van Allen, EM | 1 |
| Chen, L; Chen, Y; Deng, P; Dong, Y; Han, B; Kong, T; Liu, D; Qian, F; Yang, H; Zhang, B; Zhang, W; Zhang, Y | 1 |
| Aldrich-Wright, JR; Aputen, AD; Elias, MG; Gilbert, J; Gordon, CP; Sakoff, JA; Scott, KF | 1 |
| Arenare, L; Artioli, G; Baldassarre, G; Beltrame, L; Califano, D; Campanini, N; Capoluongo, ED; Cecere, SC; Chiodini, P; Cinieri, S; Colombo, N; D'Incalci, M; De Cecio, R; Llop-Guevara, A; Lorusso, D; Marchini, S; Mezzanzanica, D; Musolino, A; Nardelli, C; Normanno, N; Pellegrino, B; Perrone, F; Pignata, S; Pisano, C; Roma, C; Russo, D; Scaglione, GL; Scambia, G; Sergi, A; Serra, V; Setaro, M; Spina, A; Tasca, G | 1 |
| Aderibigbe, BA; Alven, S; Buyana, B; Naki, T | 1 |
| Enzinger, PC; Guo, H; Joo, S; Meng, Y; Qu, T; Zhang, S; Zhong, Y | 1 |
| Cheng, Y; Cui, J; Lin, C; Peng, Z; Qian, K; Wu, R; Yin, W | 1 |
| Ahmed, R; Attia, M; Hanna, D; Kamal, NM; Oshi, MAM; Rifky, E; Sherief, LM | 1 |
| Ahmed, N; Goonetilleke, L; Kadife, E; Kannourakis, G; Leung, D; Lokman, NA; Oehler, MK; Price, ZK; Ricciardelli, C; Wang, W | 1 |
| de Korte-Grimmerink, R; Decollogny, M; Domanitskaya, N; Essers, P; Fendler, W; Galván, JA; Howald, D; Huijbers, IJ; Klebic, I; Nowicka, Z; Pritchard, CEJ; Rottenberg, S; Siffert, M; Stokar-Regenscheit, N; van de Ven, M; Vens, C; Widmer, CA | 1 |
| Akeroyd, MA; Baguley, DM; Pearson, SE; Phillips, OR | 1 |
| Czeleń, P; Szefler, B | 1 |
| Akerley, W; Haaland, B; Kerrigan, K; Patel, S; Puri, S; Sama, S; Sinnott, JA | 1 |
| Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P | 1 |
| Adamo, V; Cantale, O; Castorina, L; Chillari, F; Colarossi, C; Esposito, F; Franchina, T; Giuffrida, D; Puliafito, I; Ricciardi, GRR; Russo, A; Sciacca, D; Vitale, MP | 1 |
| Eom, JS; Jo, EJ; Kim, KU; Kim, MH; Kim, SH; Lee, K; Lee, MK; Mok, J; Park, HK | 1 |
| Han, Z; Hong, Z; Li, S; Qin, Y; Wang, L; Wang, X; Zhu, D | 1 |
| Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E | 1 |
| Endo, J; Fujii, H; Fukui, M; Gomyo, T; Hirose, C; Iihara, H; Inui, T; Kaito, D; Kawae, D; Kinomura, M; Kitamura, YU; Kobayashi, R; Ohno, Y; Sakai-Masuda, C; Sasaki, Y; Suzuki, A; Yanase, K | 1 |
| Albertella, MR; Bani, MR; Decio, A; Dellavedova, G; Formenti, L; Ghilardi, C; Giavazzi, R; Leo, E; Staniszewska, AD; Wilson, J | 1 |
| Bonomo, P; Borcoman, E; Cau, MC; Depenni, R; Ghi, MG; Ghiani, M; Le Tourneau, C; Leo, L; Messinger, D; Montesarchio, V; Ronzino, G; Salmio, S; Sbrana, A; Schulten, J | 1 |
| Artaç, M; Bozcuk, H; Eser, İ; Mutlu, H | 1 |
| Bleckmann, A; Frost, N; Griesinger, F; Grohé, C; Janning, M; Kollmeier, J; Reck, M; Reinmuth, N; Sebastian, M; Thomas, M | 1 |
| Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Noyman, E | 1 |
| Borgonovo, K; Celotti, A; Ghidini, A; Lorusso, D; Luciani, A; Petrelli, F; Rea, CG; Solinas, C; Villa, A | 1 |
| Enamorado, Y; Han, D; López-Mesas, M; Luaces, M; Melchior, A; Sanadar, M; Valiente, M | 1 |
| Gu, X; Guan, Y; Hao, Y; Song, Z; Sun, Y; Wang, W; Xiang, J; Yao, Q; Zeng, X | 1 |
| Bhanegaonkar, A; Bilen, MA; Kim, R; Liu, FX; Peng, J; Robinson, SB; Schroeder, A | 1 |
| Augusto, I; Cruz, A; Mansinho, A; Marconi, L; Pinto, C | 1 |
| Akamatsu, H; Hida, T; Inui, N; Kang, JH; Kim, HR; Lee, JS; Lee, KH; Nakagawa, K; Nishio, M; Ohe, Y; Sugawara, S; Takahashi, S; Tamura, T; Tanaka, H; Yamamoto, N; Yang, CT; Yoshida, T; Yu, CJ | 1 |
| Chiavarino, B; Corinti, D; Crestoni, ME; Fornarini, S; Rotari, L; Salpin, JY; Scuderi, D | 1 |
| Cedrés, S; Hansen, TB; Herrera-Juarez, M; Isambert, N; Jaderberg, M; Lederlin, M; Levitsky, V; Martinez-Marti, A; Navarro, A; Paz-Ares, L; Ponce, S; Ricordel, C; Serres, X; Vetrhus, S; Viteri, S; Zugazagoitia, J | 1 |
| Beith, J; Dear, RF; Egger, SJ; Goodwin, A; Mason, SR; Willson, ML | 1 |
| Aiba, T; Domeki, Y; Kawana, S; Kawashima, Y; Kimura, Y; Nakamura, A; Sugawara, S; Sugisaka, J; Toi, Y; Yamanda, S | 1 |
| Cormier, L; Lui, S; Middleton, L; Ndinguri, M; Nienaber, E; Rollins, J; Spease, C; Unrine, J; Williams, A | 1 |
| Hara, Y; Hashimoto, H; Horita, N; Kaneko, A; Kaneko, T; Kobayashi, N; Kubo, S; Kudo, M; Matsumoto, H; Somekawa, K; Teranishi, S; Watanabe, K | 1 |
| Ahn, S; Bao, K; Choi, HS; Kang, H; Kim, J; Park, SH; Stiles, WR; Yamashita, A; Zeng, L | 1 |
| Abro, MI; Jahangir, TM; Khaskheli, MA; Khaskheli, MI; Khokhar, FM; Khokhar, LA; Khuhawar, MY; Muqaddisa, P | 1 |
| Aoyagi, K; Boonstra, E; Cabral, H; Hong, T; Ono, R; Perkins, EJ; Quader, S; Sasaki, H; Tanabe, S; Yokozaki, H | 1 |
30 review(s) available for platinum and carboplatin
| Article | Year |
|---|---|
Clinical pharmacokinetics of carboplatin.
Topics: Administration, Oral; Animals; Blood Proteins; Bone Marrow; Carboplatin; Cisplatin; Humans; Injections, Intraperitoneal; Injections, Intravenous; Neoplasms; Platinum; Protein Binding; Tissue Distribution | 1991 |
Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Infant, Newborn; Meta-Analysis as Topic; Ovarian Neoplasms; Platinum; Randomized Controlled Trials as Topic; Survival Rate | 1991 |
Carboplatin as a potentiator of radiation therapy.
Topics: Animals; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Cricetinae; Cricetulus; Humans; Mice; Neoplasms; Organoplatinum Compounds; Platinum; Radiation-Sensitizing Agents | 1985 |
Platinum resistance: laboratory findings and clinical implications.
Topics: Animals; Carboplatin; Cisplatin; Drug Resistance; Humans; Platinum | 1993 |
Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Drug Design; Humans; Kinetics; Neoplasms; Nucleosides; Nucleotides; Palladium; Platinum; Purines; Pyrimidines | 1996 |
[Platinum compounds in cancer therapy--past, present, and future].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Forecasting; Humans; Irinotecan; Medical Oncology; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum | 2001 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Meta-Analysis as Topic; Platinum; Standard of Care | 2012 |
New strategies against prostate cancer--Pt(II)-based chemotherapy.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Platinum; Prostatic Neoplasms | 2012 |
Understanding platinum-induced ototoxicity.
Topics: Animals; Antineoplastic Agents; Carboplatin; Child; Cisplatin; Ear Diseases; Humans; Neoplasms; Platinum; Quality of Life; Risk Factors | 2013 |
Increasing the chances for platinum-sensitive ovarian cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
The role of annexin A4 in cancer.
Topics: Annexin A4; Calcium; Carboplatin; Chlorides; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Male; Neoplasms; NF-kappa B; Platinum; Up-Regulation | 2016 |
Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Carboplatin; Cation Transport Proteins; Cisplatin; DNA Adducts; Humans; Neoplasms; Neurons; Organoplatinum Compounds; Oxaliplatin; Platinum | 2017 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Platinum; Prospective Studies; Retrospective Studies | 2020 |
Role of Platinums in Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Neoadjuvant Therapy; Platinum; Triple Negative Breast Neoplasms | 2021 |
The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Platinum; Progression-Free Survival; Triple Negative Breast Neoplasms | 2021 |
Advancements in the Use of Platinum Complexes as Anticancer Agents.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Neoplasms; Oxaliplatin; Platinum | 2022 |
Platinum-based drugs for cancer therapy and anti-tumor strategies.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Neoplasms; Oxaliplatin; Platinum | 2022 |
Clinical Evidence of Interaction between Nutraceutical Supplementation and Platinum-based Chemotherapy.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Dietary Supplements; Humans; Platinum; Quality of Life | 2023 |
Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Hearing Loss; Humans; Neoplasms; Ototoxicity; Platinum | 2022 |
A chemical perspective on the clinical use of platinum-based anticancer drugs.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Oxaliplatin; Platinum | 2022 |
Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Colorectal Neoplasms; Female; Humans; Male; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Platinum | 2022 |
Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estrogens; Humans; Platinum; Randomized Controlled Trials as Topic; Receptors, Progesterone; Triple Negative Breast Neoplasms | 2022 |
The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review.
Topics: Adult; Antineoplastic Agents; Cancer Survivors; Carboplatin; Child; Cisplatin; Hearing Loss; Humans; Neoplasms; Ototoxicity; Platinum; Quality of Life; Tinnitus | 2023 |
Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum; Vitamin B Complex | 2023 |
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2023 |
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Network Meta-Analysis; Ovarian Neoplasms; Platinum; Polyethylene Glycols | 2023 |
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Topics: B7-H1 Antigen; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Platinum; Urinary Bladder Neoplasms | 2023 |
Platinum-based chemotherapy for early triple-negative breast cancer.
Topics: Adjuvants, Immunologic; Anthracyclines; Carboplatin; Febrile Neutropenia; Humans; Platinum; Quality of Life; Triple Negative Breast Neoplasms | 2023 |
41 trial(s) available for platinum and carboplatin
| Article | Year |
|---|---|
Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adducts.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cheek; Cisplatin; DNA; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Leukocytes; Male; Middle Aged; Mouth Mucosa; Platinum | 1991 |
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
Topics: Carboplatin; Cisplatin; DNA; DNA Damage; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukocytes; Male; Neoplasms; Platinum; Prospective Studies; Spectrophotometry, Atomic | 1991 |
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Carboplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Organoplatinum Compounds; Platinum | 1989 |
Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Topics: Adult; Antineoplastic Agents; Carboplatin; Cisplatin; Head and Neck Neoplasms; Humans; Middle Aged; Organoplatinum Compounds; Platinum | 1987 |
[Pharmacokinetic analysis of platinum in the continuous CDDP-CBDCA treatment; its relation to the changes of blood biochemistry].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Cisplatin; Creatinine; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Platinum; Uterine Neoplasms | 1995 |
A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count.
Topics: Adenocarcinoma; Aged; Carboplatin; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Male; Middle Aged; Monte Carlo Method; Ovarian Neoplasms; Platelet Count; Platinum; Risk Factors; Teratoma; Testicular Neoplasms; Thrombocytopenia | 1994 |
Phase I study of WR-2721 and carboplatin.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Platinum; Thrombocytopenia | 1993 |
In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Leukocyte Count; Ovarian Neoplasms; Pilot Projects; Platelet Count; Platinum; Tumor Cells, Cultured | 1993 |
Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Injections, Intravenous; Male; Middle Aged; Platinum; Reproducibility of Results; Saliva; Spectrophotometry, Atomic | 1995 |
[Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Alprostadil; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Epirubicin; Etoposide; Female; Humans; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Mitomycin; Platinum; Uterine Cervical Neoplasms; Vindesine | 1996 |
Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cisplatin; DNA Adducts; Female; Humans; Leukocytes, Mononuclear; Male; Mass Spectrometry; Middle Aged; Neoplasms; Platinum | 1996 |
Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study.
Topics: Adolescent; Adult; Antineoplastic Agents; Autopsy; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Female; Ganglia, Spinal; Humans; Male; Middle Aged; Platinum; Sural Nerve | 1999 |
A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.
Topics: Acridines; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; DNA Adducts; Drug Interactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Platinum; Pyrazoles | 2002 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Stomach Neoplasms | 2005 |
Distribution of platinum in the female genital tract and efficacy of radiotherapy combined with transcatheter arterial infusion of cisplatin for locally advanced stage IIIb carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Female; Genitalia, Female; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Lymph Nodes; Middle Aged; Neoplasm Staging; Platinum; Radiotherapy; Uterine Cervical Neoplasms | 2009 |
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Recurrence | 2010 |
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Platinum; Polyethylene Glycols; Recurrence; Treatment Outcome | 2012 |
Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cyclobutanes; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Platinum; Thrombocytopenia; Vomiting | 2013 |
Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Platinum; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Transcription Factors; Transcription Initiation Site; Treatment Outcome; Young Adult | 2013 |
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Topics: Adult; Aged; Carboplatin; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Radiotherapy Dosage; Small Cell Lung Carcinoma | 2013 |
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Platinum | 2014 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; Disease-Free Survival; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Survival Rate | 2015 |
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Platinum; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Young Adult | 2015 |
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
Tumor
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Carboplatin; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Triple Negative Breast Neoplasms | 2017 |
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Tre
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Double-Blind Method; Etoposide; Humans; Lung Neoplasms; Picornaviridae; Platinum | 2020 |
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind
Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Preparations; Platinum; Quality of Life; Randomized Controlled Trials as Topic; Selenium | 2021 |
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Etoposide; Humans; Indoles; Lung Neoplasms; Platinum; Prospective Studies; Quinolines; Small Cell Lung Carcinoma | 2022 |
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Paclitaxel; Platinum | 2022 |
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Ipilimumab; Neoadjuvant Therapy; Nivolumab; Platinum; Urinary Bladder Neoplasms | 2022 |
A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms | 2022 |
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Purines | 2022 |
Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2023 |
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Topics: Bevacizumab; Carboplatin; Female; Homologous Recombination; Humans; Mangifera; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerases | 2022 |
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin | 2023 |
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Thyroid Nuclear Factor 1 | 2023 |
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis | 2023 |
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.
Topics: Carboplatin; Cisplatin; Humans; Mesothelioma, Malignant; Pemetrexed; Platinum; Tumor Microenvironment | 2023 |
249 other study(ies) available for platinum and carboplatin
| Article | Year |
|---|---|
Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Confidence Intervals; Cyclophosphamide; Doxorubicin; Female; Humans; Meta-Analysis as Topic; Ovarian Neoplasms; Platinum; Randomized Controlled Trials as Topic; Survival Rate | 1992 |
A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro).
Topics: Animals; Antineoplastic Agents; Blood Proteins; Carboplatin; Cisplatin; Male; Mice; Mice, Inbred Strains; Organoplatinum Compounds; Platinum; Protein Binding; Radioisotopes; Rats; Rats, Wistar; Sensitivity and Specificity; Structure-Activity Relationship | 1992 |
Comparative study of cisplatin and carboplatin on pharmacokinetics, nephrotoxicity and effect on renal nuclear DNA synthesis in rats.
Topics: Animals; Blood Urea Nitrogen; Carboplatin; Cisplatin; Creatinine; DNA; Kidney; Male; Platinum; Rats; Rats, Inbred Strains | 1992 |
The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Carboplatin; Carcinoma; Cisplatin; Erythrocytes; Female; Humans; Liver; Male; Middle Aged; Osteosarcoma; Ovarian Neoplasms; Platinum; Teratoma; Testicular Neoplasms; Time Factors | 1992 |
5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Resistance; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Remission Induction | 1992 |
The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cisplatin; Drug Resistance; Glutathione; Leukemia L1210; Mice; Organoplatinum Compounds; Platinum; Sensitivity and Specificity; Tumor Cells, Cultured | 1992 |
Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.
Topics: Carboplatin; Cisplatin; Drug Resistance; Female; Humans; Ovarian Neoplasms; Platinum; Salvage Therapy | 1992 |
[Pharmakinetics of carboplatin in cancer patients].
Topics: Adult; Breast Neoplasms; Carboplatin; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum | 1991 |
A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Topics: Adenocarcinoma; Animals; Body Temperature; Carboplatin; Colonic Neoplasms; Combined Modality Therapy; Hyperthermia, Induced; Injections, Intraperitoneal; Injections, Intravenous; Male; Peritoneal Neoplasms; Platinum; Rats; Tissue Distribution | 1992 |
The effect of platinum complexes on human skin cells in vivo and in vitro.
Topics: Administration, Topical; Animals; Carboplatin; Cells, Cultured; Cisplatin; Epidermal Cells; Fibroblasts; Humans; In Vitro Techniques; Keratinocytes; Mice; Mice, Hairless; Platinum; Skin | 1991 |
Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
Topics: Adenocarcinoma; Breast Neoplasms; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; DNA; Drug Resistance; Glutathione Transferase; Humans; Lung Neoplasms; Melanoma; Neoplasms; Organoplatinum Compounds; Platinum; Sulfhydryl Compounds; Tumor Cells, Cultured | 1991 |
Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Topics: Antineoplastic Agents; Biological Assay; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Organoplatinum Compounds; Platinum; Tumor Cells, Cultured | 1991 |
Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
Topics: Animals; Carboplatin; Cell Line; Cell Survival; Cisplatin; Colony-Forming Units Assay; DNA; Humans; Platinum; Spectrophotometry, Atomic; Thymidine; Tumor Cells, Cultured | 1991 |
[Evaluation of carboplatin administration into the serous cavity in the treatment of malignant effusion].
Topics: Aged; Carboplatin; Drug Evaluation; Female; Humans; Injections, Intralesional; Lung Neoplasms; Male; Middle Aged; Platinum; Pleural Effusion, Malignant | 1991 |
Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Radioisotopes; Time Factors | 1991 |
Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds.
Topics: Animals; Antioxidants; Ascorbic Acid; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Iron; Kidney; Lipid Peroxidation; Male; Microsomes; Phenylenediamines; Platinum; Rats; Rats, Inbred Strains; Stereoisomerism; Time Factors | 1991 |
Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats.
Topics: Animals; Carboplatin; Injections, Intravenous; Kidney; Male; Platinum; Rats; Rats, Inbred Strains | 1991 |
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
Topics: Adult; Aged; Carboplatin; DNA, Neoplasm; Drug Administration Schedule; Drug Evaluation; Female; Glomerular Filtration Rate; Humans; Infusions, Intravenous; Kidney; Leukopenia; Male; Middle Aged; Neoplasms; Platinum; Regional Blood Flow; Remission Induction | 1991 |
A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Cell Line; Cisplatin; Coloring Agents; Drug Resistance; Drug Screening Assays, Antitumor; Glutathione; Humans; Lung Neoplasms; Organoplatinum Compounds; Platinum; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1990 |
Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study.
Topics: Animals; Carboplatin; Cisplatin; Gluconeogenesis; Glucose-6-Phosphatase; In Vitro Techniques; Kidney Diseases; Male; Malondialdehyde; Microsomes; Organoplatinum Compounds; p-Aminohippuric Acid; Platinum; Rabbits; Rats; Rats, Inbred Strains; Species Specificity; Tetraethylammonium Compounds | 1990 |
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Cohort Studies; DNA; Female; Humans; Leukocytes; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Prognosis | 1990 |
The effects of the platinum anti-tumour agents on renal cell kinetics and the response to a second cytotoxic agent.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Division; Cell Survival; Cisplatin; Cytotoxins; Epithelial Cells; Epithelium; Kidney; Mice; Organoplatinum Compounds; Platinum; Uranyl Nitrate | 1990 |
The tissue distribution in rats of [195mPt]carboplatin following intravenous, intraperitoneal and oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carboplatin; Injections, Intraperitoneal; Injections, Intravenous; Male; Organoplatinum Compounds; Platinum; Radioisotopes; Rats; Rats, Inbred Strains; Tissue Distribution | 1990 |
Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cisplatin; Cyanides; Half-Life; Intestinal Absorption; Intestine, Small; Male; Nitrogen; Organoplatinum Compounds; Platinum; Rats; Rats, Inbred Strains | 1990 |
In vivo toxicity of cisplatin and carboplatin on the Leydig cell function and effect of the human choriogonadotropin.
Topics: Animals; Carboplatin; Chorionic Gonadotropin; Cisplatin; Cytochrome P-450 Enzyme System; Leydig Cells; Male; Microsomes; Organoplatinum Compounds; Platinum; Rats; Rats, Inbred Strains; Testosterone | 1989 |
Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Survival; Chlorides; DNA, Superhelical; Hot Temperature; Mice; Organoplatinum Compounds; Platinum; Platinum Compounds | 1989 |
[Pharmacokinetics of new cisplatin analogues in experimental animals].
Topics: Animals; Antineoplastic Agents; Carboplatin; Cisplatin; Mice; Organoplatinum Compounds; Platinum; Protein Binding; Rabbits; Sarcoma 180; Tissue Distribution | 1989 |
[Present status of cisplatin (CDDP) analogues in Japan].
Topics: Antineoplastic Agents; Carboplatin; Chemical Phenomena; Chemistry; Cisplatin; Female; Humans; Kidney; Leukopenia; Nervous System; Organoplatinum Compounds; Platinum; Protein Binding; Thrombocytopenia | 1989 |
Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Creatinine; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Organoplatinum Compounds; Platinum; Spectrophotometry, Atomic; Ultrafiltration | 1989 |
An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin.
Topics: Animals; Antineoplastic Agents; Autoradiography; Carboplatin; Cisplatin; Isotope Labeling; Kidney; Male; Mice; Organoplatinum Compounds; Platinum; Quality Control; Radioisotopes | 1988 |
The disposition of carboplatin in ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Protein Binding | 1988 |
Pharmacokinetics of carboplatin after intraperitoneal administration.
Topics: Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Injections, Intraperitoneal; Middle Aged; Organoplatinum Compounds; Peritoneal Cavity; Platinum | 1988 |
Platinum levels in murine tumor following intraperitoneal administration of cisplatin or paraplatin.
Topics: Animals; Carboplatin; Cisplatin; Combined Modality Therapy; Female; Injections, Intraperitoneal; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Organoplatinum Compounds; Platinum | 1988 |
Clinical pharmacokinetics of carboplatin.
Topics: Antineoplastic Agents; Carboplatin; Chromatography, High Pressure Liquid; Cisplatin; DNA; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Organoplatinum Compounds; Platinum; Protein Binding; Spectrophotometry, Atomic | 1988 |
[Pharmacokinetics of carboplatin (CBDCA) and tissue concentration of platinum in gynecologic organs].
Topics: Antineoplastic Agents; Blood Platelets; Blood Urea Nitrogen; Carboplatin; Cervix Uteri; Erythrocytes; Female; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Organoplatinum Compounds; Ovary; Platinum; Uterus | 1988 |
The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin.
Topics: Animals; Biotransformation; Carbon Radioisotopes; Carboplatin; Ileum; Kidney; Liver; Mice; Mice, Inbred BALB C; Muscles; Organoplatinum Compounds; Platinum; Tissue Distribution | 1988 |
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Glomerular Filtration Rate; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Platinum | 1987 |
Pharmacokinetics of carboplatin after i.v. administration.
Topics: Carboplatin; Carcinoma; Female; Humans; Injections, Intravenous; Organoplatinum Compounds; Ovarian Neoplasms; Platinum | 1987 |
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma 256, Walker; Cell Survival; Cells, Cultured; Cisplatin; DNA; Humans; Kinetics; Nucleic Acid Conformation; Organoplatinum Compounds; Plasmids; Platinum | 1986 |
Uptake of platinum compounds in human tumors. In vitro study.
Topics: Aged; Antineoplastic Agents; Carboplatin; Cells, Cultured; Cisplatin; Dose-Response Relationship, Drug; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Organoplatinum Compounds; Pharyngeal Neoplasms; Platinum; Time Factors | 1986 |
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Topics: Biological Transport; Cadmium; Carboplatin; Carcinoma, Squamous Cell; Cell Line; Cell Membrane; Cisplatin; Drug Resistance; Glutathione Transferase; Humans; Metallothionein; Organoplatinum Compounds; Platinum; Structure-Activity Relationship; Sulfhydryl Compounds | 1987 |
Microscale syntheses of anti-tumour platinum compounds labelled with 191Pt.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Isotope Labeling; Organoplatinum Compounds; Platinum; Radioisotopes | 1985 |
Phase I study and pharmacokinetics of intraperitoneal carboplatin.
Topics: Antineoplastic Agents; Carboplatin; Drug Evaluation; Humans; Kinetics; Neoplasms; Organoplatinum Compounds; Platinum | 1985 |
[Development of antitumor platinum complexes].
Topics: Animals; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclohexylamines; Humans; Kidney; Neoplasms; Neoplasms, Experimental; Organoplatinum Compounds; Platinum; Structure-Activity Relationship | 1983 |
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Topics: Antineoplastic Agents; Carboplatin; Drug Evaluation; Humans; Kidney; Kinetics; Neoplasms; Organoplatinum Compounds; Platinum | 1984 |
Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Drug Evaluation; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Platinum; Pleural Effusion; Thrombocytopenia | 1984 |
In vivo and in vitro effectivity of some platinum complexes.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Line; Cisplatin; Drug Evaluation, Preclinical; Female; Injections, Intraperitoneal; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Male; Mice; Mice, Inbred DBA; Organoplatinum Compounds; Platinum | 1984 |
Binding characteristics of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-2-platin um(II) to DNA, RNA and protein molecules in HeLa cells and its lethal effect: comparison with cis- and trans-diamminedichloroplatinums(II).
Topics: Carboplatin; Cell Division; Cell Survival; Cisplatin; DNA; HeLa Cells; Humans; Platinum; Proteins; RNA | 1994 |
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; DNA; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Germinoma; Humans; Leukocytes; Male; Middle Aged; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic; Testicular Neoplasms; Vinblastine | 1994 |
Platinum concentrations in uterus and serum after internal iliac arterial infusion of platinum compounds in rabbits.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cisplatin; Female; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Jugular Veins; Organoplatinum Compounds; Platinum; Rabbits; Uterus | 1995 |
[The study of platinum concentration in retroperitoneal lymph nodes after intraperitoneal carboplatin in ovarian tumors].
Topics: Adult; Aged; Carboplatin; Carcinoma; Cystadenocarcinoma, Mucinous; Female; Humans; Infusions, Parenteral; Lymph Nodes; Middle Aged; Ovarian Neoplasms; Platinum; Retroperitoneal Space | 1995 |
Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks.
Topics: Animals; Carboplatin; Cells, Cultured; Cricetinae; DNA Adducts; DNA Damage; DNA Repair; DNA, Single-Stranded; Platinum; Radiation Tolerance | 1995 |
Detection of platinum-DNA adducts by 32P-postlabelling.
Topics: Animals; Carboplatin; Chromatography, Ion Exchange; Cisplatin; DNA; DNA Adducts; Female; Isotope Labeling; Phosphorus Radioisotopes; Platinum; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity | 1995 |
Differential toxicity of cisplatin, carboplatin, and CI-973 correlates with cellular platinum levels in rat renal cortical slices.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cisplatin; In Vitro Techniques; Kidney Cortex; Male; Platinum; Protein Biosynthesis; Proteins; Rats; Rats, Wistar | 1995 |
Effect of ultrafilterable platinum concentration on cisplatin and carboplatin cytotoxicity in human tumor and bone marrow cells in vitro.
Topics: Bone Marrow; Carboplatin; Cisplatin; Culture Media; Humans; Platinum; Protein Binding; Tumor Cells, Cultured; Ultrafiltration | 1994 |
Analysis of enloplatin by liquid chromatography and of platinum by atomic absorption spectrometry in various biological fluids.
Topics: Animals; Antineoplastic Agents; Carboplatin; Chromatography, Liquid; Dogs; Freezing; Humans; Indicators and Reagents; Platinum; Quality Control; Rats; Spectrophotometry, Atomic; Ultrafiltration | 1994 |
Potentiation of cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) by amphotericin B in BALB/c nude mice bearing human ovarian carcinoma cells.
Topics: Amphotericin B; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Synergism; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Ovarian Neoplasms; Platinum | 1994 |
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Specimen Collection; Carboplatin; Cisplatin; DNA Adducts; DNA Repair; DNA, Neoplasm; Etoposide; Humans; Kinetics; Leukocytes; Neoplasms; Platinum | 1995 |
Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Topics: Animals; Antineoplastic Agents; Carboplatin; Circadian Rhythm; Erythrocytes; Male; Mice; Mice, Inbred Strains; Organoplatinum Compounds; Oxaliplatin; Plasma; Platinum; Protein Binding | 1994 |
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Topics: Animals; Carboplatin; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fibrosarcoma; Interleukin-1; Mice; Mice, Inbred C3H; Platinum; Receptors, Interleukin-1; Time Factors; Tumor Cells, Cultured | 1994 |
Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption.
Topics: Adolescent; Adult; Blood-Brain Barrier; Brain; Brain Neoplasms; Carboplatin; Cisplatin; Etoposide; Female; Germinoma; Hearing Loss, High-Frequency; Humans; Magnetic Resonance Imaging; Male; Mannitol; Platinum; Treatment Outcome | 1994 |
Cerebral metastases from epithelial ovarian carcinoma treated with carboplatin.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum | 1994 |
[A study of intra-arterial infusion with carboplatin (CBDCA) for 2 patients with maxillary gingival cancer].
Topics: Aged; Carboplatin; Carcinoma, Squamous Cell; Female; Gingival Neoplasms; Humans; Infusions, Intra-Arterial; Male; Maxilla; Platinum | 1994 |
[Distribution of platinum in the female genital tract after intraarterial carboplatin infusion during the operation of uterine cervical cancer].
Topics: Adenocarcinoma; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Genitalia, Female; Humans; Infusions, Intra-Arterial; Intraoperative Care; Lymph Nodes; Platinum; Uterine Cervical Neoplasms | 1994 |
A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin.
Topics: Base Composition; Base Sequence; Binding Sites; Carboplatin; Chromatography, High Pressure Liquid; Cisplatin; DNA; DNA Damage; Electrophoresis, Agar Gel; Hydrogen-Ion Concentration; Kinetics; Molecular Sequence Data; Nucleic Acid Conformation; Plasmids; Platinum | 1994 |
Initial measurements of platinum concentration in head and neck tumors using X-ray fluorescence.
Topics: Body Composition; Carboplatin; Cisplatin; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Platinum; Spectrometry, X-Ray Emission; Technetium | 1993 |
[Pharmacokinetics of carboplatin in a patient under hemodialysis].
Topics: Carboplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Middle Aged; Ovarian Neoplasms; Platinum; Renal Dialysis | 1994 |
Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
Topics: Animals; Carboplatin; Cell Survival; Cisplatin; DNA; DNA Adducts; Dose-Response Relationship, Drug; Hot Temperature; Platinum; Rats; Tumor Cells, Cultured | 1993 |
Enhanced formation of reactive species from cis-diammine-(1,1-cyclobutanedicarboxylato)-platinum(II) (carboplatin) in the presence of oxygen free radicals.
Topics: Animals; Ascorbic Acid; Carboplatin; Cisplatin; DNA; Drug Stability; Edetic Acid; Ferrous Compounds; Free Radicals; Oxygen; Platinum | 1993 |
Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; DNA; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Male; Middle Aged; Mouth Mucosa; Neoplasms; Pilot Projects; Platinum | 1993 |
Massive cisplatin overdose by accidental substitution for carboplatin. Toxicity and management.
Topics: Aged; Carboplatin; Cisplatin; DNA Repair; DNA-Binding Proteins; Drug Overdose; Female; Humans; Plasmapheresis; Platinum | 1993 |
Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells.
Topics: Biological Transport; Carboplatin; Cell Survival; Dose-Response Relationship, Drug; HeLa Cells; Hot Temperature; Humans; Kinetics; Platinum; Time Factors | 1993 |
Comparison of carboplatin pharmacokinetics between an anephric child and two children with normal renal function.
Topics: Blood Proteins; Brain Neoplasms; Carboplatin; Child, Preschool; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Kidney; Nephrectomy; Platinum; Protein Binding; Renal Dialysis; Ultrafiltration; Wilms Tumor | 1993 |
Platinum complex-induced dysfunction of cultured renal proximal tubule cells. A comparative study of carboplatin and transplatin with cisplatin.
Topics: Animals; Carboplatin; Cell Survival; Cells, Cultured; Cisplatin; DNA; Enzymes; Glucose; Glutathione; Kidney Tubules, Proximal; Microvilli; Opossums; Organoplatinum Compounds; Platinum; Protein Biosynthesis; Rabbits; Sodium-Potassium-Exchanging ATPase; Succinate Dehydrogenase | 1993 |
Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
Topics: Animals; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Choriocarcinoma; Cisplatin; Humans; Models, Biological; Platinum; Skin; Swine; Tumor Cells, Cultured; Vascular Resistance | 1993 |
A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Linear Models; Male; Middle Aged; Ovarian Neoplasms; Platinum; Prospective Studies; Protein Binding; Regression Analysis; Reproducibility of Results; Retrospective Studies | 1996 |
Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations.
Topics: Blood Proteins; Carboplatin; Chemical Precipitation; Cisplatin; Ethanol; Humans; Platinum; Spectrophotometry, Atomic; Trichloroacetic Acid; Ultrafiltration | 1996 |
Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cohort Studies; Combined Modality Therapy; Feasibility Studies; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome | 1996 |
[Intraperitoneal administration of carboplatin loaded alpha-tricalcium phosphate (alpha-TCP) particles in rats bearing abdominal carcinomatosis].
Topics: Animals; Antineoplastic Agents; Ascites; Biodegradation, Environmental; Calcium Phosphates; Carboplatin; Disease Models, Animal; Drug Carriers; Infusions, Parenteral; Male; Peritoneal Neoplasms; Platinum; Rats | 1996 |
Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Radiotherapy Dosage; Survival Analysis | 1997 |
Inhibitory effects of platinum anticancer agents on rat brain protein kinase C.
Topics: Animals; Antineoplastic Agents; Brain; Carboplatin; Cisplatin; Enzyme Inhibitors; Male; Organoplatinum Compounds; Platinum; Protein Kinase C; Rats; Rats, Wistar | 1997 |
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Body Temperature; Carboplatin; DNA Adducts; Drug Administration Schedule; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Platinum; Radiation-Protective Agents; Transplantation, Heterologous | 1997 |
A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Drug Administration Schedule; Drug Tolerance; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Platinum | 1997 |
Determination of the target volume of HeLa cells treated with platinum-195 m radiolabeled cis-diammine(1, 1-cyclobutane-dicarboxylato)-platinum(II); comparison with cis- and trans-diamminedichloroplatinums(II).
Topics: Antineoplastic Agents; Carboplatin; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; HeLa Cells; Humans; Isotopes; Platinum | 1994 |
Internal iliac arterial infusion chemotherapy for rabbit invasive bladder cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Invasiveness; Platinum; Rabbits; Urinary Bladder Neoplasms | 1997 |
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Treatment Outcome | 1998 |
Monitoring local disposition kinetics of carboplatin in vivo after subcutaneous injection in rats by means of 195Pt NMR.
Topics: Animals; Antineoplastic Agents; Carboplatin; Chlorides; Cisplatin; Dimethyl Sulfoxide; Dimethylformamide; Electron Spin Resonance Spectroscopy; Injections, Subcutaneous; Magnetic Resonance Spectroscopy; Male; Neck; Platinum; Platinum Compounds; Rats; Rats, Wistar; Signal Processing, Computer-Assisted; Skin; Solvents; Water | 1998 |
Quantitative imaging microscopy for the sensitive detection of administered metal containing drugs in single cells and tissue slices--a demonstration using platinum based chemotherapeutic agent.
Topics: Animals; Antineoplastic Agents; Carboplatin; CHO Cells; Cisplatin; Cricetinae; Kidney Tubules; Male; Platinum; Rats; Rats, Inbred F344; Sensitivity and Specificity; Spectrometry, X-Ray Emission | 1998 |
Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative.
Topics: Breast Neoplasms; Carboplatin; Cell Size; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Drug Stability; Female; Humans; Magnetic Resonance Spectroscopy; Ovarian Neoplasms; Platinum; Serum Albumin; Solubility; Tumor Cells, Cultured | 1998 |
European hospitals as a source for platinum in the environment in comparison with other sources.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Environmental Pollution; Europe; Hospitals; Humans; Medical Waste; Platinum; Sewage; Vehicle Emissions; Water Pollution, Chemical | 1999 |
1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Carboplatin; Cell Cycle; Cell Division; Cholecalciferol; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Platinum; Prostatic Neoplasms; Tumor Cells, Cultured | 1999 |
Determination of platinum (II,IV) and palladium(II) as thiocyanate complexes by capillary zone electrophoresis analysis of carboplatin and similar drugs.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Electrophoresis, Capillary; Palladium; Platinum; Spectrophotometry; Thiocyanates; Vehicle Emissions | 1999 |
Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay.
Topics: Anticoagulants; Antineoplastic Agents; Blood Specimen Collection; Calibration; Carboplatin; Drug Stability; Edetic Acid; Heparin; Humans; Platinum; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Atomic; Temperature; Time Factors; Ultrafiltration | 1999 |
In vivo measurement of platinum in the kidneys using X-ray fluorescence.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Kidney; Neoplasms; Organoplatinum Compounds; Photons; Platinum; Scattering, Radiation; Sensitivity and Specificity; Spectrometry, X-Ray Emission | 2000 |
Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival.
Topics: Animals; Antineoplastic Agents; Bradykinin; Brain Neoplasms; Carboplatin; Glioma; Infusions, Intravenous; Male; Paclitaxel; Platinum; Rats; Rats, Inbred F344 | 2000 |
Intraperitoneal chemotherapy and intraperitoneal washing cytology in management of ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Female; Humans; Infusions, Parenteral; Neoplasm, Residual; Ovarian Neoplasms; Peritoneal Lavage; Platinum; Reoperation; Survival Analysis | 2000 |
Chemotherapy for malignant mixed Müllerian tumors of the ovary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin.
Topics: Age Factors; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Surface Area; Carboplatin; Cyclophosphamide; Female; Humans; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platelet Count; Platinum; Prospective Studies; Thrombocytopenia | 2001 |
Synthesis, characterization and antitumor activity of quinolone-platinum(II) conjugates.
Topics: Animals; Antineoplastic Agents; Carboplatin; Fluoroquinolones; Leukemia L1210; Magnetic Resonance Spectroscopy; Models, Chemical; Molecular Structure; Nalidixic Acid; Oxolinic Acid; Platinum; Quinolizines; Quinolones; Spectrophotometry, Infrared; Tumor Cells, Cultured | 2001 |
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Follow-Up Studies; Humans; Middle Aged; Models, Theoretical; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Treatment Outcome | 2002 |
Topotecan as first-line therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan | 2003 |
Kinetic study on the reactions of platinum drugs with glutathione.
Topics: Antineoplastic Agents; Carboplatin; Chromatography, High Pressure Liquid; Cisplatin; Glutathione; Kinetics; Organoplatinum Compounds; Oxaliplatin; Platinum; Spectrophotometry, Ultraviolet | 2004 |
Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate.
Topics: Animals; Antineoplastic Agents; Brain Stem; Carboplatin; Infusion Pumps; Injections, Intraperitoneal; Macaca fascicularis; Male; Platinum; Pons | 2004 |
Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Carboplatin; Cation Transport Proteins; Cell Division; Cisplatin; Copper; Copper-Transporting ATPases; DNA; Fibroblasts; Humans; Microscopy; Organoplatinum Compounds; Oxaliplatin; Platinum; Recombinant Fusion Proteins; Transfection | 2004 |
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Biological Transport; Carboplatin; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Copper; Copper-Transporting ATPases; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Kinetics; Microscopy, Confocal; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Recombinant Fusion Proteins; Time Factors | 2004 |
Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters.
Topics: Amino Acid Motifs; Antineoplastic Agents; Blotting, Western; Carboplatin; Cation Transport Proteins; Cell Line; Chelating Agents; Cisplatin; Copper; Copper Transporter 1; Cycloheximide; Dimerization; Dimethyldithiocarbamate; DNA, Complementary; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Endocytosis; Humans; Immunoblotting; Methionine; Microscopy, Fluorescence; Models, Biological; Mutagenesis; Organoplatinum Compounds; Oxaliplatin; Platinum; Protein Binding; Protein Structure, Tertiary; Protein Synthesis Inhibitors; Time Factors; Transfection | 2004 |
Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors.
Topics: Animals; Area Under Curve; Blood Cell Count; Blood Platelets; Carboplatin; Cat Diseases; Cats; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Neoplasms; Neutrophils; Platinum; Regression Analysis; Spectrophotometry, Atomic; Technetium Tc 99m Pentetate | 2004 |
[Comparison of pelvic transarterial chemoembolization with lipiodol ultra-fluid carboplatin and transarterial carboplatin through experiment in dogs].
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carboplatin; Chemoembolization, Therapeutic; Dogs; Female; Iliac Artery; Infusions, Intra-Arterial; Iodized Oil; Platinum; Random Allocation; Uterus | 2004 |
Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane.
Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Carboplatin; Carcinoma, Hepatocellular; Cell Cycle; Cisplatin; Colorectal Neoplasms; Cyclohexylamines; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Isomerism; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum; Tumor Cells, Cultured | 2006 |
High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Line, Transformed; Cells, Cultured; Cisplatin; DNA Adducts; Ear, Inner; Epithelial Cells; Guanosine; Guinea Pigs; Hydrogen Peroxide; Injections, Intraperitoneal; Kidney Tubules; Kinetics; Microscopy, Fluorescence; Platinum; Rats; Stria Vascularis; Tissue Distribution | 2006 |
Role of platinum-based radio-chemotherapy for locally advanced non-small-cell lung cancer: possible influence of type of platinum on survival data.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Platinum; Survival Analysis | 2006 |
Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin.
Topics: Carboplatin; Drug Compounding; Drug Screening Assays, Antitumor; Endocytosis; Humans; Nanoparticles; Phospholipids; Platinum; Structure-Activity Relationship; Tumor Cells, Cultured | 2006 |
Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Topics: Antineoplastic Agents; Calibration; Carboplatin; Cisplatin; Humans; Indicators and Reagents; Mass Spectrometry; Organoplatinum Compounds; Oxaliplatin; Platinum; Quality Control; Reference Standards; Reproducibility of Results; Ultrafiltration | 2006 |
Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cisplatin; Cross Reactions; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum; Prognosis; Prospective Studies; Salts; Skin Tests | 2007 |
Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Female; Humans; Male; Mass Spectrometry; Myosarcoma; Neoplasms; Neoplasms, Muscle Tissue; Platinum; Rhabdomyosarcoma | 2006 |
Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition).
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytotoxins; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Platinum; Quality of Life; Treatment Outcome | 2007 |
Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Fractionation; Cisplatin; Cytosol; Ear, Inner; Kidney; Liver; Mass Spectrometry; Organoplatinum Compounds; Oxaliplatin; Platinum; Rats; Tissue Distribution | 2008 |
Catheters for chronic administration of drugs into brain tissue.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain; Brain Neoplasms; Carboplatin; Catheterization; Dogs; Doxorubicin; Drug Delivery Systems; Female; Glioma; Macaca fascicularis; Male; Neoplasm Transplantation; Neurosurgical Procedures; Pharmaceutical Preparations; Platinum; Rats; Rats, Inbred F344; Spectrophotometry, Atomic; Tissue Distribution | 2008 |
Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Platinum; Sarcoma; Sarcoma 180 | 2008 |
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.
Topics: Animals; Carboplatin; Cation Transport Proteins; Cell Line, Tumor; Cells, Cultured; Cisplatin; Copper Transporter 1; Mice; Organoplatinum Compounds; Oxaliplatin; Platinum | 2009 |
Interstitial continuous infusion therapy in a malignant glioma model in rats.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carboplatin; Catheterization; Cell Line, Tumor; Corpus Striatum; Disease Models, Animal; Glioma; Kaplan-Meier Estimate; Male; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Platinum; Rats; Rats, Inbred F344; Treatment Outcome | 2009 |
Targeted delivery of chemotherapeutic agents using improved radiosensitive liquid core microcapsules and assessment of their antitumor effect.
Topics: Alginates; Animals; Antineoplastic Agents; Calcium; Calcium Chloride; Capsules; Carboplatin; Cobalt Radioisotopes; Colorimetry; Combined Modality Therapy; Drug Compounding; Fibrosarcoma; Glucuronic Acid; Hexuronic Acids; Hyaluronic Acid; Mice; Mice, Inbred BALB C; Platinum; Polymers; Time Factors; Yttrium | 2009 |
Peptide targeting of platinum anti-cancer drugs.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Caspases; CD13 Antigens; Cell Line, Tumor; DNA Fragmentation; Drug Delivery Systems; Female; Humans; Male; Molecular Targeted Therapy; Oligopeptides; Platinum | 2009 |
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Topics: Animals; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Platinum; Transplantation, Heterologous | 2009 |
Determination of platinum traces contamination by graphite furnace atomic absorption spectrometry after preconcentration by cloud point extraction.
Topics: Carboplatin; Chemical Precipitation; Cisplatin; Decontamination; Ditiocarb; Octoxynol; Organoplatinum Compounds; Oxaliplatin; Platinum; Platinum Compounds; Polyethylene Glycols; Spectrophotometry, Atomic | 2010 |
On the many roles of NH3 ligands in mono- and multinuclear complexes of platinum.
Topics: Ammonia; Antineoplastic Agents; Carboplatin; Cisplatin; Coordination Complexes; Crystallography, X-Ray; Hydrogen Bonding; Ligands; Molecular Conformation; Platinum | 2009 |
Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: synthesis and comparison with carboplatin in normal and Pt-resistant cell lines.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Coordination Complexes; Drug Resistance, Neoplasm; Humans; Metalloporphyrins; Platinum | 2009 |
Synthesis, characterization, cytotoxicity, and DNA binding of some new platinum(II) and platinum(IV) complexes with benzimidazole ligands.
Topics: Antineoplastic Agents; Benzimidazoles; Carboplatin; Cell Line, Tumor; Cisplatin; DNA; Humans; Ligands; Nucleic Acid Conformation; Organometallic Compounds; Plasmids; Platinum | 2010 |
Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.
Topics: Asian People; Black People; Carboplatin; Cell Line, Transformed; Cisplatin; Genetic Predisposition to Disease; Genetic Variation; Genetics, Population; Genome-Wide Association Study; Humans; Inhibitory Concentration 50; Lymphocytes; Pharmacogenetics; Phenotype; Platinum; White People | 2010 |
Transcription inhibition by platinum-DNA cross-links in live mammalian cells.
Topics: Antineoplastic Agents; Base Sequence; Carboplatin; Cell Line, Tumor; Cisplatin; Cross-Linking Reagents; DNA; DNA Adducts; DNA Damage; DNA Repair; DNA-Directed RNA Polymerases; Genes, Reporter; Humans; Organoplatinum Compounds; Oxaliplatin; Plasmids; Platinum; Transcription, Genetic | 2010 |
Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.
Topics: Carboplatin; Cisplatin; Etoposide; Female; Genes; Genome; Humans; Inuit; Lung Neoplasms; Male; Middle Aged; Nerve Tissue Proteins; Platinum; Polymorphism, Single Nucleotide; R-SNARE Proteins; Small Cell Lung Carcinoma | 2010 |
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy.
Topics: Animals; Carboplatin; Cisplatin; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles; Nanotechnology; Neoplasms; Platinum; Polyenes; Polymers; Raloxifene Hydrochloride; Structure-Activity Relationship; Tissue Distribution | 2010 |
Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands.
Topics: Adenine; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; HeLa Cells; Hepatocytes; Humans; Inhibitory Concentration 50; Molecular Structure; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Palladium; Platinum | 2010 |
Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry.
Topics: Animals; Antineoplastic Agents; Calibration; Carboplatin; Cerumen; Dogs; Humans; Indicators and Reagents; Limit of Detection; Platinum; Quality Control; Reference Standards; Reproducibility of Results; Sebum; Sensitivity and Specificity; Spectrum Analysis | 2011 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry.
Topics: Animals; Antineoplastic Agents; Carboplatin; Dogs; Feces; Humans; Platinum; Reproducibility of Results; Saliva; Spectrophotometry, Atomic | 2011 |
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.
Topics: Antineoplastic Agents; Biomarkers; Carboplatin; Cell Line; Genome-Wide Association Study; Head and Neck Neoplasms; Humans; Models, Biological; Platinum; Polymorphism, Genetic; Treatment Outcome | 2011 |
Inelastic neutron scattering study of Pt(II) complexes displaying anticancer properties.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Coordination Complexes; Neutron Diffraction; Platinum; Scattering, Small Angle | 2011 |
Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor.
Topics: Adsorption; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Cell Line, Tumor; Cisplatin; Coordination Complexes; Diphosphonates; Durapatite; Humans; Neoplasm Metastasis; Osteoclasts; Platinum | 2011 |
Adamantane-platinum conjugate hosted in β-cyclodextrin: enhancing transport and cytotoxicity by noncovalent modification.
Topics: Adamantane; Antineoplastic Agents; beta-Cyclodextrins; Carboplatin; Cell Line, Tumor; Cell Survival; Drug Carriers; Fluorescein-5-isothiocyanate; Humans; Mass Spectrometry; Microscopy, Confocal; Plasmids; Platinum | 2011 |
Pharmacokinetics, tissue distribution, and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supramolecule, in rats and dogs by ICP-MS.
Topics: Animals; Antineoplastic Agents; Carboplatin; Dogs; Drug Combinations; Drug Screening Assays, Antitumor; Glutamates; Half-Life; Injections, Intravenous; Male; Mass Spectrometry; Organoplatinum Compounds; Platinum; Prostate; Protein Binding; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Testis; Time Factors; Tissue Distribution | 2012 |
Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs.
Topics: Antineoplastic Agents; Arsenic; Biomarkers; Carboplatin; Chile; Cisplatin; Cluster Analysis; Creatinine; Female; Humans; Linear Models; Lung Neoplasms; Male; Multivariate Analysis; Platinum; Selenium | 2012 |
Capillary liquid chromatography with UV detection using N,N-diethyl dithiocarbamate for determining platinum-based antitumor drugs in plasma.
Topics: Animals; Antineoplastic Agents; Carboplatin; Chromatography, High Pressure Liquid; Cisplatin; Injections, Intraperitoneal; Male; Organoplatinum Compounds; Platinum; Rats; Rats, Wistar; Spectrophotometry, Ultraviolet; Thiocarbamates | 2012 |
Tissue platinum concentration and tumor response in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Platinum; Survival Analysis | 2012 |
The interaction of platinum-based drugs with native biologically relevant proteins.
Topics: Antineoplastic Agents; Carboplatin; Chromatography, Liquid; Cisplatin; Hemoglobins; Humans; Lactoglobulins; Organoplatinum Compounds; Oxaliplatin; Oxidation-Reduction; Platinum; Protein Binding; Serum Albumin; Sodium Chloride; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Coordination Complexes; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Ethylamines; Ethylenediamines; Humans; Models, Molecular; Molecular Conformation; Organoplatinum Compounds; Oxaliplatin; Platinum; Quantitative Structure-Activity Relationship; Thermodynamics | 2013 |
Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cerumen; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Feces; Neoplasms; Platinum; Saliva; Sebum; Spectrophotometry, Atomic | 2015 |
Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Platinum; Vinblastine; Vinorelbine | 2013 |
Caged Pt nanoclusters exhibiting corrodibility to exert tumor-inside activation for anticancer chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Dendrimers; Drug Carriers; Humans; Magnetic Resonance Imaging; Mice; Mice, Nude; Nanostructures; Neoplasms; Platinum; Radiography; Transplantation, Heterologous | 2013 |
Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Female; Glutamates; Guanine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Pemetrexed; Platinum; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; United States | 2013 |
Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry.
Topics: Animals; Antineoplastic Agents; Cancer Care Facilities; Carboplatin; Environmental Monitoring; Equipment Contamination; Humans; Mass Spectrometry; Netherlands; Occupational Exposure; Platinum | 2015 |
Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Carboplatin; Cell Line; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Organoplatinum Compounds; Platinum; Pyruvates | 2014 |
Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells.
Topics: Apoptosis; Blotting, Southwestern; Blotting, Western; Carboplatin; Carcinoma; Cell Line, Tumor; Cell Survival; Cinnamates; Cyclic N-Oxides; DNA Primers; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Gene Silencing; Humans; Laryngeal Neoplasms; Platinum; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Signal Transduction; Spin Labels; Thiourea | 2013 |
A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection.
Topics: Bacterial Proteins; Buffers; Carboplatin; Chromatography, High Pressure Liquid; Cisplatin; Humans; Hydrogen-Ion Concentration; Organoplatinum Compounds; Oxaliplatin; Platinum; Protein Binding; Reproducibility of Results; Sensitivity and Specificity; Serum Albumin; Spectrophotometry, Atomic; Transferrin | 2013 |
TCEP-based rSDS-PAGE AND nLC-ESI-LTQ-MS/MS for oxaliplatin metalloproteomic analysis.
Topics: Animals; Carbonic Anhydrases; Carboplatin; Cisplatin; Cytochromes c; Electrophoresis, Polyacrylamide Gel; Kidney; Limit of Detection; Myoglobin; Organoplatinum Compounds; Oxaliplatin; Peptide Fragments; Phosphines; Platinum; Protein Binding; Proteolysis; Rats; Serum Albumin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Transferrin; Trypsin | 2013 |
DNA polymerase η modulates replication fork progression and DNA damage responses in platinum-treated human cells.
Topics: Carboplatin; Cell Cycle; Cell Line; Cisplatin; DNA Damage; DNA Replication; DNA-Directed DNA Polymerase; Drug Synergism; Gene Expression; Humans; Phosphorylation; Platinum; Replication Protein A | 2013 |
Sequential extraction of platinum, cisplatin and carboplatin from environmental samples and pre-concentration/separation using vesicular coacervative extraction and determination by continuum source ETAAS.
Topics: Carboplatin; Chemical Fractionation; Cisplatin; Environmental Monitoring; Hydrochloric Acid; Molecular Structure; Nitric Acid; Platinum; Soil; Spectrophotometry, Atomic; Surface-Active Agents; Water | 2014 |
East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Carboplatin; Cisplatin; Coordination Complexes; DNA Adducts; HCT116 Cells; Humans; Inhibitory Concentration 50; Light; Necrosis; Optical Imaging; Organoplatinum Compounds; Platinum; Pyridines; Scattering, Radiation | 2014 |
Raman spectroscopic evaluation of DNA adducts of a platinum containing anticancer drug.
Topics: Adenine; Animals; Antineoplastic Agents; Carboplatin; Cattle; Cisplatin; Cross-Linking Reagents; DNA; DNA Adducts; Guanine; Humans; Neoplasms; Nucleic Acid Conformation; Platinum; Protein Structure, Secondary; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Thymus Gland | 2014 |
Synthesis, in-vitro cytotoxic activity and DNA interactions of new dicarboxylatoplatinum(II) complexes with 2-hydroxymethylbenzimidazole as carrier ligands.
Topics: Antineoplastic Agents; Benzimidazoles; Carboplatin; Cisplatin; DNA; Drug Screening Assays, Antitumor; Estrogens; HeLa Cells; Humans; In Vitro Techniques; Ligands; MCF-7 Cells; Neoplasms; Plasmids; Platinum; Progesterone; Progestins; Restriction Mapping | 2014 |
[Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Endonucleases; Female; Hot Temperature; Humans; Inhibitor of Apoptosis Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; RNA, Messenger; Survivin | 2014 |
A shotgun approach for the identification of platinum-protein complexes.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Peptides; Platinum; Protein Binding; Proteins; Tandem Mass Spectrometry | 2015 |
Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carboplatin; Cisplatin; Follow-Up Studies; Humans; Male; Middle Aged; Platinum; Testicular Neoplasms | 2015 |
Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Topics: Antineoplastic Agents; Bromosuccinimide; Carboplatin; Cell Line, Tumor; Cisplatin; Female; Halogenation; Humans; Models, Molecular; Organoplatinum Compounds; Ovarian Neoplasms; Ovary; Oxaliplatin; Oxidation-Reduction; Platinum; Prodrugs | 2015 |
The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Biological Transport; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Cold Temperature; Coordination Complexes; Glucose; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Oligomycins; Organoplatinum Compounds; Oxidation-Reduction; Platinum; Prodrugs; Structure-Activity Relationship | 2016 |
Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Carboplatin; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Ascitic Fluid; Carboplatin; Female; Humans; Middle Aged; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Prognosis; Vascular Endothelial Growth Factor A | 2016 |
Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Platinum; Polymers; Treatment Outcome | 2016 |
Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carboplatin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Middle Aged; Platinum; Retrospective Studies; Skin Tests | 2017 |
Elution of platinum from carboplatin-impregnated calcium sulfate hemihydrate beads in vitro.
Topics: Animals; Calcium Sulfate; Carboplatin; Microspheres; Platinum | 2016 |
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Folate Receptor 1; Humans; Immunoconjugates; Maytansine; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Xenograft Model Antitumor Assays | 2016 |
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carboplatin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mass Spectrometry; Mice; Mutation; Neoplasms; Platinum; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Chemical Imaging of Platinum-Based Drugs and their Metabolites.
Topics: Carboplatin; Chromatography, Liquid; Cisplatin; Culture Media; Ditiocarb; HCT116 Cells; Humans; Hyperthermia, Induced; Imaging, Three-Dimensional; Metabolome; Organoplatinum Compounds; Oxaliplatin; Pharmaceutical Preparations; Platinum; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spheroids, Cellular; Tandem Mass Spectrometry; Time Factors | 2016 |
Anticancer activity and tissue distribution of platinum (II) complex with lignin-derived polymer of benzene-poly-carboxylic acids.
Topics: Animals; Antineoplastic Agents; Benzene; Carboplatin; Carboxylic Acids; Carcinoma, Ehrlich Tumor; Cisplatin; Female; Lignin; Mice; Organoplatinum Compounds; Platinum; Polymers | 2017 |
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
Topics: Carboplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Ovarian Neoplasms; Platinum | 2016 |
Biological Recovery of Platinum Complexes from Diluted Aqueous Streams by Axenic Cultures.
Topics: Antineoplastic Agents; Axenic Culture; Carboplatin; Cisplatin; Cupriavidus; Environmental Monitoring; Environmental Pollutants; Environmental Restoration and Remediation; Flow Cytometry; Geobacter; Microbial Viability; Microscopy, Electron, Transmission; Platinum; Platinum Compounds; Shewanella; Wastewater; Water Purification | 2017 |
Characterization of long-term elution of platinum from carboplatin-impregnated calcium sulfate hemihydrate beads in vitro by two distinct sample collection methods.
Topics: Animals; Antineoplastic Agents; Calcium Sulfate; Carboplatin; Drug Delivery Systems; Microspheres; Platinum | 2017 |
Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Disease-Free Survival; Ethnicity; Female; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Platinum; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome | 2017 |
Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cytoskeleton; DNA, Mitochondrial; Drug Resistance, Neoplasm; Female; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Platinum; Tubulin | 2017 |
[
Topics: Animals; Carboplatin; Drug Delivery Systems; Female; Liposomes; Mice; Platinum; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon | 2017 |
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Carboplatin; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Pemetrexed; Peptides; Platinum; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2017 |
DNA interaction with platinum-based cytostatics revealed by DNA sequencing.
Topics: Carboplatin; Cisplatin; Cytostatic Agents; DNA; DNA Adducts; Mass Spectrometry; Organoplatinum Compounds; Oxaliplatin; Platinum; Polymerase Chain Reaction; Sequence Analysis, DNA | 2017 |
DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Proliferation; Checkpoint Kinase 2; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Platinum; Stomach Neoplasms; Structure-Activity Relationship; Subcellular Fractions; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Development of a carboplatin derivative conjugated with a collagen-like triple-helical peptide.
Topics: Animals; Carboplatin; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Collagen; Drug Design; Drug Stability; Half-Life; Humans; Male; Malonates; Mice; Mice, Inbred ICR; Neoplasms; Platinum; Prodrugs; Protein Structure, Secondary; Survival Rate; Transplantation, Heterologous | 2018 |
Development of a novel carboplatin like cytoplasmic trackable near infrared fluorophore conjugate via strain-promoted azide alkyne cycloaddition.
Topics: Antineoplastic Agents; Azides; Carboplatin; Cell Line, Tumor; Cell Survival; Click Chemistry; Cycloaddition Reaction; Cytoplasm; Humans; Platinum | 2018 |
Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
Topics: Benzimidazoles; Carboplatin; Humans; Neoadjuvant Therapy; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Salts; Standard of Care; Triple Negative Breast Neoplasms | 2018 |
Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2016 |
Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy.
Topics: A549 Cells; Activins; Adenocarcinoma of Lung; Animals; Carboplatin; Cell Line, Tumor; Cell Survival; Follistatin; Humans; Lung Neoplasms; Male; Mice; Platinum; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Raman and Infrared Studies of Platinum-Based Drugs: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, and Heptaplatin.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Malonates; Models, Chemical; Molecular Conformation; Organoplatinum Compounds; Oxaliplatin; Platinum; Quantum Theory; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Stereoisomerism; Vibration | 2018 |
Simulation of spatial diffusion of platinum from carboplatin-impregnated calcium sulfate hemihydrate beads by use of an agarose gelatin tissue phantom.
Topics: Animals; Calcium Sulfate; Carboplatin; Dogs; Drug Screening Assays, Antitumor; Gelatin; Inhibitory Concentration 50; Mass Spectrometry; Microspheres; Neoplasms; Phantoms, Imaging; Platinum; Sepharose; Time Factors | 2018 |
Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel.
Topics: Breast Neoplasms; Carboplatin; Cell Line, Tumor; Coordination Complexes; DNA Adducts; DNA Damage; DNA Repair; Female; Humans; Mass Spectrometry; Oxaliplatin; Platinum | 2018 |
Transport of platinum-based pharmaceuticals in water-saturated sand and natural soil: Carboplatin and cisplatin species.
Topics: Biopharmaceutics; Carboplatin; Cisplatin; Geologic Sediments; Organoplatinum Compounds; Oxidation-Reduction; Platinum; Platinum Compounds; Soil; Soil Pollutants; Water | 2019 |
A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
Topics: Antineoplastic Agents; Audiometry; Carboplatin; Child; Cisplatin; Female; Hearing Loss; Humans; Male; Neoplasms; Platinum | 2019 |
Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cohort Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome | 2019 |
A Triangular Platinum(II) Multinuclear Complex with Cytotoxicity Towards Breast Cancer Stem Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cadherins; Carboplatin; Caspases; Cell Line, Tumor; Cisplatin; Coordination Complexes; Crystallography, X-Ray; Female; Humans; Molecular Conformation; Neoplastic Stem Cells; Platinum; Pyrans; RNA Interference; RNA, Small Interfering | 2019 |
The leading established metal-based drugs: a revisitation of their relevant physico-chemical data.
Topics: Auranofin; Carboplatin; Cisplatin; Coordination Complexes; Gold; Gold Sodium Thiomalate; Merbromin; Mercury; Oxaliplatin; Phenylmercury Compounds; Platinum; Ruthenium | 2019 |
Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced
Topics: Acrylamides; Aniline Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Pharmacokinetics of platinum and safety evaluation of carboplatin-impregnated calcium sulfate hemihydrate beads after implantation in healthy cats.
Topics: Animals; Antineoplastic Agents; Calcium Sulfate; Carboplatin; Cats; Female; Platinum | 2020 |
Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Fatty Acids, Omega-3; Humans; Ototoxicity; Oxidative Stress; Platinum | 2020 |
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; MAP Kinase Signaling System; Mice; Ovarian Neoplasms; Paclitaxel; Platinum; Tumor Microenvironment | 2020 |
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Topics: Apoptosis; Breast Neoplasms; Carboplatin; Caspases; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Platinum | 2020 |
Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chloroquinolinols; Cisplatin; Cystadenocarcinoma, Serous; DNA Damage; Drug Resistance, Neoplasm; Female; Humans; Mice, Transgenic; Ovarian Neoplasms; Platinum | 2021 |
Treatment-related leukemia after taxane and platinum therapy in gynecological cancer patients (Gynecologic Oncology Trial and Investigation Consortium 011).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Genital Neoplasms, Female; Humans; Leukemia; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Taxoids | 2021 |
Comparisons of segment-specific toxicity of platinum-based agents and cadmium using S1, S2, and S3 cells derived from mouse kidney proximal tubules.
Topics: Animals; Antineoplastic Agents; Cadmium; Cadmium Chloride; Carboplatin; Cell Survival; Cells, Cultured; Cisplatin; Clusterin; Copper Transporter 1; Hepatitis A Virus Cellular Receptor 1; Kidney Tubules, Proximal; Mice; Organic Cation Transport Proteins; Organic Cation Transporter 2; Oxaliplatin; Platinum | 2021 |
Platinum-based chemotherapy and bevacizumab instigate the destruction of human ovarian cancers via different signaling pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Signal Transduction; Tumor Cells, Cultured | 2021 |
Pharmacokinetic and safety assessment of carboplatin-impregnated calcium sulfate hemihydrate beads in eight rats.
Topics: Animals; Calcium Sulfate; Carboplatin; Male; Platinum; Rats; Rats, Sprague-Dawley | 2021 |
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrazoles; Pyrimidinones | 2022 |
Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum | 2022 |
A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Male; Middle Aged; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Ovarian Neoplasms; Platinum | 2022 |
Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
Topics: Antineoplastic Agents; Carboplatin; Child; Cisplatin; Follow-Up Studies; Hearing Loss; Humans; Ototoxicity; Platinum; Platinum Compounds | 2022 |
Platinum-Based Chemotherapy 'Rechallenge' in Advanced Non-ovarian Solid Malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Platinum; Quality of Life | 2022 |
Enhancing Circulation and Tumor Accumulation of Carboplatin via an Erythrocyte-Anchored Prodrug Strategy.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Erythrocytes; Mice; Neoplasms; Platinum; Prodrugs | 2022 |
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
Topics: Biomarkers, Tumor; Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Neoplasm Staging; Neural Cell Adhesion Molecule L1; Platinum; Prognosis | 2022 |
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non-small cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2023 |
Anaphylactic reaction to carboplatin diagnosed by skin testing-a reliable tool in platinum-based immediate-type hypersensitivity reactions.
Topics: Anaphylaxis; Antineoplastic Agents; Carboplatin; Cisplatin; Drug Hypersensitivity; Erythema; Female; Humans; Melanoma; Middle Aged; Ovarian Neoplasms; Platinum | 2023 |
Severity of hearing loss after platinum chemotherapy in childhood cancer survivors.
Topics: Antineoplastic Agents; Cancer Survivors; Carboplatin; Child; Cisplatin; Hearing Loss; Humans; Neoplasms; Platinum | 2022 |
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
Topics: Ataxia Telangiectasia Mutated Proteins; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Drug Resistance; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factors; Humans; Ovarian Neoplasms; Platinum; Recombinational DNA Repair; Replication Protein A; RNA, Small Interfering | 2022 |
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Immune Checkpoint Inhibitors; Platinum; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Carboplatin; Cation Transport Proteins; Cisplatin; Copper; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Humans; Neoplasms; Peptide Fragments; Platinum; Protein Kinase C; Protein Kinase Inhibitors | 2022 |
A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Tumor Microenvironment | 2022 |
Ruthenium(II) Polypyridyl Complexes Containing Simple Dioxo Ligands: a Structure-Activity Relationship Study Shows the Importance of the Charge.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Coordination Complexes; Humans; Ligands; Malonates; Neoplasms; Oxalates; Platinum; Ruthenium; Structure-Activity Relationship | 2022 |
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2022 |
Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.
Topics: Carboplatin; Female; Humans; Ovarian Neoplasms; Platinum; Thyroid Neoplasms | 2022 |
Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Prospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2022 |
Potent Chlorambucil-Platinum(IV) Prodrugs.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Chlorambucil; Cisplatin; Female; Humans; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Prodrugs; Reactive Oxygen Species | 2022 |
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cost-Benefit Analysis; Delivery of Health Care; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Platinum; Quality-Adjusted Life Years; Trastuzumab | 2022 |
Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association.
Topics: Cancer Survivors; Carboplatin; Child; Cisplatin; Cross-Sectional Studies; Deafness; Glutathione S-Transferase pi; Hearing Loss; Humans; Neoplasms; Ototoxicity; Platinum | 2022 |
Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Topics: Aldehyde Reductase; Carboplatin; Carcinoma, Ovarian Epithelial; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Ovarian Neoplasms; Platinum; Proteomics; RNA, Messenger; Tumor Microenvironment | 2022 |
Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy.
Topics: Animals; Anions; Carboplatin; Cisplatin; Membrane Proteins; Mice; Platinum; Prospective Studies; Tumor Suppressor Protein p53 | 2022 |
Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Topics: Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2023 |
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia | 2023 |
Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients With Thoracic Cancer Receiving Platinum-based Chemotherapy.
Topics: Antiemetics; Carboplatin; Humans; Mirtazapine; Nausea; Platinum; Retrospective Studies; Serotonin; Thoracic Neoplasms; Vomiting | 2023 |
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Topics: Adenocarcinoma; Animals; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Models, Animal; Female; Heterografts; Humans; Mice; Ovarian Neoplasms; Platinum; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
Topics: Animals; Carboplatin; Drug Resistance, Neoplasm; Female; Humans; Mesenchymal Stem Cells; Mice; Ovarian Neoplasms; Platinum; Tumor Microenvironment | 2023 |
Comparative study on removal of platinum cytostatic drugs at trace level by cysteine, diethylenetriamino functionalized Si-gels and polyethyleneimine functionalized sponge: Adsorption performance and mechanisms.
Topics: Adsorption; Carboplatin; Cisplatin; Cysteine; Cytostatic Agents; DEET; Hydrogen-Ion Concentration; Kinetics; Platinum; Polyethyleneimine; Silica Gel; Thermodynamics; Water; Water Pollutants, Chemical | 2023 |
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Medicare; Platinum; Retrospective Studies; United States; Urinary Bladder Neoplasms | 2023 |
Binding Motifs of Carboplatin and Oxaliplatin with Guanine: A Combined MS/MS, IRMPD, and Theoretical Study.
Topics: Carboplatin; Guanine; Oxaliplatin; Platinum; Spectrophotometry, Infrared; Tandem Mass Spectrometry | 2023 |
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2023 |
Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Female; Gonadotropin-Releasing Hormone; Humans; Platinum; Receptors, LHRH; Triple Negative Breast Neoplasms | 2023 |
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
H-Dot Mediated Nanotherapeutics Mitigate Systemic Toxicity of Platinum-Based Anticancer Drugs.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cardiotoxicity; Cisplatin; Neoplasms; Platinum | 2023 |
Analysis of platinum-based anticancer injections cisplatin and carboplatin in blood serum and urine of cancer patients by photometry, fluorometry, liquid chromatography using a Schiff-base as derivatizing reagent.
Topics: Carboplatin; Chromatography, High Pressure Liquid; Cisplatin; Fluorometry; Humans; Indicators and Reagents; Ligands; Neoplasms; Platinum; Serum | 2024 |
Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Immediate-Early Proteins; MicroRNAs; Oxaliplatin; Platinum; Trypsin Inhibitor, Kazal Pancreatic; Tumor Microenvironment; Tumor Suppressor Proteins | 2023 |